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ABSTRACT

Schenk, Désirée K.E. Ph.D., Purdue University, December 2014. Silica Nanoparticles for
Therapy Delivery in Neurological Injury. Major Professors: Dr. James F. Leary and Dr.
Riyi Shi.

Acrolein, a very reactive aldehyde, is a culprit in the biochemical cascade after primary,
mechanical spinal cord injury (SCI), which leads to the destruction of tissue initially
unharmed, referred to as “secondary injury”. Additionally, in models of multiple sclerosis
(MS) and some clinical research, acrolein levels are significantly increased. This
aldehyde overwhelms the natural anti-oxidant system, reacts freely with proteins, and
releases during lipid peroxidation (LPO), effectively regenerating its self. Due to its
ability to make more copies of itself in the presence of tissue via lipid peroxidation,
researchers believe that acrolein plays a role in the increased destruction of the central
nervous system in both SCI and MS. Hydralazine, an FDA-approved hypertension drug,
has been shown to scavenge acrolein, but its side effects and short half life at the
appropriate dose for acrolein scavenging must be improved for beneficial clinical
translation. Due to the inefficient delivery of therapeutic drugs, nanoparticles have
become a major field of exploration for medical applications. Based on their material
properties, they can help treat disease by delivering drugs to specific tissues, enhancing
detection methods, or a mixture of both. Nanoparticles made from silica provide distinct
advantages. They form porous networks that can carry therapeutic molecules throughout

xvi
the body. Therefore, a nanomedical approach has been designed using silica
nanoparticles as a porous delivery vehicle hydralazine. The silica nanoparticles are
formed in a one-step method that incorporates poly(ethylene) glycol (PEG), a stealth
molecule, directly onto the nanoparticles. As an additional avenue for study, a natural
product in green tea, epigallocatechin gallate (EGCG), has been explored for its ability to
react with acrolein, disabling its reactive capabilities. Upon demonstration of attenuating
acrolein, EGCG's delivery may also be improved using the nanomedical approach. The
nanoparticles' physical characteristics were characterized and their interactions in vitro
were studied for cytotoxicity and potential activity in attenuating neuronal damage.

1

CHAPTER 1. INTRODUCTION

1.1

Rationale

SCI results in concentrated cell death and leads to a feed forward process of oxidative
stress that affects healthy tissues around the injury site. The current therapies for SCI fail
to address the many issues and biochemical events that occur both during and following
initial injury. Some of the therapies address the initial injury while others help to alleviate
effects of secondary injury. Therefore, a new therapeutic system is essential to move
forward in alleviating the disabling effects of SCI. An effective therapy for SCI would
possess the following characteristics:






It must have an anti-oxidant property to alleviate the stress on the natural
glutathione system and address the oxidative stress in secondary injury.
It must help to reduce membrane damage in injured neurons to help restore their
ability to conduct action potentials.
It must improve upon current therapies in not only therapeutic value but side
effects must also be reduced.
It must be deemed safe and nontoxic at therapeutically-relevant levels.

Nanomedicine has the advantage over conventional medicine in that it has the potential to
address many problems in one therapeutic vehicle without prescribing a large, eclectic
cocktail of therapeutic drugs. The creation of a nanomedical system using silica
nanoparticles will help to alleviate effects of acrolein after SCI. Prolonging the
circulation time with mesoporous silica nanoparticles loaded with hydralazine would
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decrease the necessary dose and increase its chance of reaching the injury site. In using a
nanomedical approach, the following criteria must be met:





Cost-effective, reproducible synthesis of nanoparticles with similar qualities and
characteristics.
The nanomedical system must effectively deliver the therapy of interest via
targeting or a similar mechanism.
It must be biologically stable, compatible, and of low toxicity.

Therefore, a therapy that addresses these points has potential to transform and expand the
current knowledge of the field. A system such as this also has direct clinical translation.
Particularly, hydralazine has already undergone FDA approval. Upon demonstrating the
safety and efficacy of the delivery vehicle, the nanomedicine has a chance to make its
way into an approved, effective therapy.

1.2

Specific aims

Aim I: Design, synthesize, and characterize hybrid silica nanoparticles. There are
various ways to create silica nanoparticles. A rather simple synthesis that eliminates the
need to graft or add PEG in a later step involves the co-condensation of PEG with the
starting siloxane, which has been demonstrated.[1, 2] Both groups also published the
chemical spectra of the nanoparticles, which can be confirmed upon synthesizing the
nanoparticles. Other nanoparticle characterization includes size, zeta potential, and
stability.
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Aim II: Evaluate the toxicity of nanoparticles in vitro. For in vitro studies, the
nanoparticles would have to show low toxicity to cells. Population-based assays that
monitor cell activity are commonly used to determine cytotoxicity, but they should be
corroborated with analysis methods such as cytometry that analyze the characteristics of
an individual cell. Particularly for looking at cell uptake, toxic effects may differ between
cells that are merely exposed to nanoparticles and those that internalize the nanoparticles.

Aim III: Explore natural products as potential acrolein scavengers. Although
hydralazine has been shown to attenuate acrolein, other scavengers may prove more
effective. An additional aim of this project is to explore the use of a natural product found
in green tea, epigallocatechin gallate (EGCG), for its potential as a potent antioxidant.

Aim IV: Explore therapy-nanoparticle interactions in a cell-free system. The
behavior of the nanoparticle-drug complex will behave differently than the nanoparticles
or therapeutic alone. This aim will achieve to define how the nanoparticles react with free
therapeutics in a solution-based system.

Aim V: Evaluate the efficacy of nanoparticles in vitro. Ultimately, the goal of the
nanomedical system is to improve therapeutic delivery through prolonged activity or
reduced degradation of the therapeutic product. This aim is to evaluate whether the
nanoparticles achieve this goal.

4

CHAPTER 2. BACKGROUND

2.1

Neurological disease

Neurological injury often results from biological damage, such as multiple sclerosis
(MS), or mechanical damage, such as compression in spinal cord injury (SCI).
Regardless of the affliction, a patient’s quality of life is likely reduced due to the loss of
motor, sensory, or cortical function. Based on epidemiological studies, MS affects many
more women than men and Caucasian women are more likely to have the disease than
women of other races.[3, 4] In MS, the body attacks two proteins that hold the protective,
neuronal myelin sheaths together: myelin basic protein (MBP) and myelin
oligodendrocyte glycoprotein (MOG).[5] The MBP amino acid composition was fully
sequenced in the early 1970’s, after much work had already been established regarding its
role in the nervous system. The sequence supported indications of the protein’s function
and location within the myelin.[6] Alternatively, MOG, the other major myelin protein,
has a large, open active site that antibodies easily tag for attack in MS patients.[5] The
cause for the sudden attack is still unclear, but research continues to explore both
biological and environmental factors.[7, 8, 9]

SCI and traumatic brain injury (TBI) are traumas to the central nervous system (CNS).
Motor vehicle accidents most heavily contribute to the occurrence of CNS injuries. Since
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young adults and teens are most likely to be involved in these types of accidents, their
age group is significantly affected.[10] Aside from possible mortality, injury usually
results in impaired motor capabilities (paralysis), sensory capabilities (hypersensitivity
and hyposensitivity), and/or neurologically-based pain. This can drastically reduce a
patient’s quality of life and place a large burden on society, both in health care costs and
lost productivity. Regardless of how the CNS is damaged, it has adverse effects on a
patient. The origin of these three neurodegenerative disorders is summarized in Table 2.1.
Although not ideal, therapies have been developed for the different conditions, but
discussed later, the treatments may have little effect or adverse side effects, which calls
for a new approach to treating disease.

Table 2.1. Summary of MS and SCI/TBI

Origin

Symptoms
Risk Factors
Affected
populations
(United States)
Treatment
References

MS
Auto-immune response to
myelin-associated proteins in
spinal cord
Lesions of the brain and
spinal cord, mobility and
cognitive impairment
Some linked genetic and
environmental risks

SCI/TBI
Mechanical or chemical
damage to brain or spinal cord
Paralysis, cognitive
impairment, death
Concussions, motor vehicle
accidents

Most common in Caucasian
women

Occurs more frequently in
males and ages 14-24

Immunosuppressants and
immunomodulators
[3, 4, 5, 6, 9, 11, 12]

Surgery and
methylprednisolone
[10, 13, 14, 15]
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2.2

Nanotechnology: A new medical approach

Nanotechnology holds promise in aiding to treat chronic disease and medical conditions.
In biology and medicine, the field has developed rapidly in the last decade to create a
new segment of nanotechnology: nanomedicine. Major goals of the field involve the
improvement of drug delivery, diagnostic or imaging techniques, and theranosis, which is
a combination of both. It gives rise to therapies that can be tailored to diagnose and treat
for specific disease states while diminishing the side effects of traditional medicine.
Additionally, as the field broadens, it expands to include nanopharmacology and
nanotoxicity for the exploration of how the body reacts to the new, nano-sized structures.

Figure 2.1. Representation of a nanomedical system adapted from Prow et al.[16]

The composition of nanoparticles is extremely diverse. They have been synthesized using
a wide range of materials: metal (e.g. gold, silver, cadmium), metal oxides (iron oxide,
titanium oxide, zinc oxide), silica, polymers, biological molecules (peptides and DNA),
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among others.[17, 18, 19, 20] As the field has progressed, more nanoparticles are being
made from mixtures of these materials, which provide new benefits and functions for the
various applications that a single material will not possess. Many times, the
amalgamation allows both the diagnostic and therapeutic effects to occur either
simultaneously or in a time-dependent manner. This is achieved by making nanoparticles
one a layer at a time, called layer-by-layer synthesis. Each layer changes a nanoparticle's
characteristics and adds functionality, essentially making the nanoparticle programmable.
The multi-functional nanoparticles become a unique nanomedical system used to address
a biological problem. An example is shown in Figure 2.1.

2.3
2.3.1

Neurological disease pathology: Overview
Neurological degeneration in spinal cord injury

Although it can recover somewhat, generally, the CNS recovers very little after injury.
On the other hand, the peripheral nervous system (PNS) recovers more efficiently. The
enzymatic and molecular composition of the neurons contributes heavily to the
differences in their regeneration. The CNS myelin, composed of oligodendrocytes,
contains direct inhibitors of axonal growth, such as the aptly-named Nogo receptor, that
interact with myelin proteins.[21, 22, 23, 24, 25] In the PNS, protective Schwann cells
form a scaffold that allows the renewed growth of injured axons.[26, 27, 28] Injury to the
CNS also affects a patient more critically. The brain and spinal cord are the control
centers for the body's many functions. When messages cannot be transported back and
forth, the brain cannot relay appropriate responses to incoming sensory information, or it
does not receive the information at all. In the PNS, although the loss of information may
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be detrimental, it is usually both locally concentrated and less critical than the copious
amounts of information the brain and spinal cord both sends and receives. In the CNS,
the axons of the neurons can be quite long, and once damaged or destroyed, the
information from a large part of the body is lost.

In places in and around the injury site, cells often suffer from membrane and myelin
damage.[15] Neuronal membrane integrity is critical to cellular function. The membrane
not only retains chemicals and proteins but also prevents them from entering. A neuron’s
function depends on specific ion concentration gradients between the extracellular and
intracellular spaces. Extracellularly, sodium and calcium ions are abundant in comparison
to the cytosol. Intracellularly, the potassium ion concentration is much higher inside the
cell. In a normal cell, the differences in concentration create a voltage potential across the
membrane and polarize the cell.[29] When the membrane is compromised, allowing the
free movement of ions, the gradients diminish or disappear. The cell depolarizes, and the
leaky membrane prevents it from repolarizing, thereby destroying its ability to generate
an action potential. Beyond that, other chemicals, such as reactive species and proteins,
can invade and damage the cell, generating secondary injury and necrosis in a cycle. The
cycle of stress and death impedes the cells’ abilities to recover from the inundation of
toxins and return to homeostasis.

In the CNS, oligodendrocytes are responsible for myelinating neuronal axons. The
oligodendrocytes form segments of sheaths around the axons. The spaces between the
segments are called the nodes of Ranvier. The sheaths allow action potentials to “jump”
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quickly from node to node.[29] Furthermore, the junctions contain distinct enzymes and
signaling molecules to keep different ion channels segregated. The nodes of Ranvier
contain potassium channels, and the sodium channels congregate in the adjacent
juxtanodal regions. The channels open and close at different points during an action
potential, and not only does the separation of the ion channels allow the movement of the
action potential, but it also facilitates faster depolarization along the axon.[30, 31] When
the ion channels do not remain separated, neuronal function is impaired.[30] Therefore,
after demyelination, when the ion channels are desegregated, the neuron’s ability to
transmit action potentials is hindered or destroyed. Beyond SCI, demyelination is a large
issue in the progression of other neurodegenerative diseases, such as MS.[5, 32]

At a deeper level, initial SCI results in a concentrated site of necrotic cell death,
membrane damage, and often, myelin damage. In opposition to apoptosis, where cell
contents are packaged and recycled before cell death, the contents of necrotic cells are
released haphazardly into their environment. Normally, the body uses many of the
molecules that are released during necrosis for various mechanisms, including signaling,
degradation, and synthesis.[33, 34, 35, 36, 37] Hydrogen peroxide and nitric oxide, both
potent oxidative species, are secondary messengers for different cellular pathways.[34,
36] For instance, nitric oxide is a secondary messenger that results in vasodilation of
smooth muscle, among other functions.[34] To help destroy invading pathogens,
hydrogen peroxide is secreted by cells responsible for immunity.[35] The superoxide
anion is produced in the mitochondria during the electron transport chain. The
combination of superoxide and nitric oxide results in peroxynitrite, and its formation and
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sequestration by uric acid after SCI was studied and found to ameliorate some effects of
peroxynitrite formation, but the major mechanism seemed to stem from attenuating the
inflammatory response from immune cells.[38] Vitamin B12 works specifically through a
radical reaction with cobalt, creating upstream products for DNA synthesis.[33] Upon the
uncontrolled release, though, many of these molecules and enzymes, specifically reactive
oxygen species (ROS) and reactive nitrogen species (RNS) (Figure 2.2), travel to
neighboring cells, including healthy ones, and cause secondary damage through effects
such as lipid peroxidation (LPO) and inflammation.[38, 39, 40]

N O

Nitric oxide

O O

Superoxide anion

HO OH

O
N O
O

Hydrogen peroxide

Peroxynitrite

Figure 2.2. Common ROS and RNS. The formation of such species is normally highly
controlled for specific signaling mechanisms (nitric oxide), respiration (superoxide), or
defense (hydrogen peroxide). When cells are damaged, radicals can freely form and
travel to uninjured, healthy cells. Environmental factors may also contribute to the
formation of oxidative stress. Therefore, reducing oxidative stress is a critical field for
nanomedicine to address.

2.3.2

Biochemical targets of SCI

In both SCI and MS, inflammation plays a role in the health and progression of the CNS
neurons. In vitro, activated microglial cells induce oxidative stress when cultured with
neuronal cells.[41, 42] Although the response is natural, the oxidative stress can be
detrimental to cells that are already undergoing stress. Furthermore, when the body
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attacks its own cells, such as in MS, the sites are pervasive rather concentrated. Figure
2.3 highlights the role inflammation can hold in neuronal injury.

Necrosis releases cellular contents (primary)

Inflammation and ROS/Acrolein

Lipid peroxidation

Membrane and myelin damage

Loss of function and homeostasis

Figure 2.3. Progression of primary injury and secondary injury. After primary injury, the
biochemical cascade that follows is secondary injury. The secondary injury can cause
damage to tissue that was previously unharmed, perpetuating a cycle of oxidative stress
and injury.

Acrolein (Figure 2.4), a reactive oxygen species, has been implicated in secondary injury
in neuronal tissues.[43, 44] Both studies found increased LPO specifically caused by
acrolein. Luo et al. monitored acrolein's protein adducts after spinal cord injury in vivo.
They found that acrolein levels peaked 24 hours after injury, but stayed elevated for up to
a week.[44] Later studies explored the various biochemical changes caused by acrolein
in neuronal tissues, including LPO, myelin damage, and mitochondrial damage.[45, 46,
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47] Acrolein's primary carbon can undergo nucleophilic (nucleus-loving) attack, but
contributing to its destructive nature, the electrophilic (electron-loving or electron
deficient) carbons of the π-bond (second bond of C=C) can undergo attack by
nucleophiles in the cell. Specifically, acrolein reacts with amine-containing lysine
residues, histidines, and electrophilic unsaturated fatty acids. When acrolein attacks fatty
acids, more is generated in a cycle of uncontrolled LPO.[48] Environmentally, it is a byproduct in the burning of plastics, overheated cooking oil, and cigarette smoke, which
makes it an important environmental source of oxidative stress that can adversely affect
the body.[49, 50, 51]

O
H2C

Figure 2.4. Acrolein is a reactive oxygen species implicated in secondary injury after
SCI. The pi-bond reacts with proteins and lipids, altering the function of proteins or
causing lipid peroxidation. The carbonyl of acrolein is still free for other reactions, such
as those used for scavenging.

When acrolein reacts with lipids, such as those in the cell membrane, the membrane is
compromised, and more acrolein is released to attack other tissue in a feed forward
process (Figure 2.5). It creates a cascade of oxidative stress to a particular area of injury.
In this way, acrolein can increase the stress and damage healthy tissues surrounding the
injury site.[39, 45, 52] The large amount of oxidative stress overwhelms the body's
natural anti-oxidant, glutathione.[53] Normally, glutathione is oxidized, which stops ROS
and RNS from oxidizing proteins and structures in the cell. It then would be reduced to
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its original form by glutathione reductase. In a large area of oxidation, glutathione cannot
be reduced quickly enough to account for the overwhelming, cyclic, and unchecked
production of acrolein. Furthermore, the protein adducts of acrolein cause functional and
conformational changes in the proteins and is hypothesized to contribute to the plaques
that form in AD.[54]

Figure 2.5. Representation of secondary injury caused by acrolein travelling from a
primary injury site to healthy tissue.

Although other biological factors may play a role in spinal cord injury, such as various
molecular pathways, inflammation and acrolein are two targets that current therapy
(discussed in the next section) does not sufficiently address. Particularly, acrolein's
persistence in vivo leads to more oxidative stress that can travel to healthy tissues,
causing the injury site to grow beyond the initial trauma point. Furthermore, unlike other
oxidative species, its levels remain high, which hinders the tissues' abilities to recover
effectively. Specifically, both acrolein and inflammation can lead to necrosis, which
negatively impacts not only the dying tissue, but also the surrounding tissue. In a
sensitive area like the spinal cord, necrosis and damage can affect the entire body, not
just a concentrated area.
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2.4

Therapeutic explorations in treating spinal cord injury
2.4.1

Immunosuppressant

Although methylprednisolone, a steroid, is the most common drug used for spinal cord
injury, it has received criticism.[55] Hugenholtz et al. concluded that the drug is too
expensive to prescribe with the current clinical data that is scattered and
inconclusive.[55] Bracken et al. recommend that the drug be given within the first eight
hours post-injury to be effective.[14] Regardless, the drug aims to suppress the immune
system, reducing inflammation around the injury site. Although it may attenuate
oxidative stress and cytokines from immune cells, it does not address the process of stress
from the dead or dying cells. Therefore, more work needs to be done to find new and
more effective therapies for spinal cord injury.

2.4.2

Glutathione

A seemingly easy approach for improving the body's stores of antioxidants includes
glutathione supplementation (Figure 2.6). The molecule is made from cysteine, glycine,
and glutamate, and its anti-oxidant properties stem from the nucleophilic thiol group of
the cysteine. Oxidative species are electrophilic, and the extra valence electrons of the
thiol group reduce the oxidative species and create water in the process. In other words,
the anti-oxidant is oxidized rather than allowing essential parts of the cell from being
oxidized. Unfortunately, orally-administered glutathione itself is poorly absorbed.[56]
Studies of glutathione levels found that it forms an equilibrium with its amino acid
components through synthesis of glutathione and uptake of cysteine.[57, 58] Therefore,
to increase glutathione levels, rather than absorbing glutathione, increasing the uptake of
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its amino acid components shifts the equilibrium towards synthesis of glutathione, which
is both a precarious balance and takes time.

SH

O

O
HO

NH

NH
NH2

O
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O

Figure 2.6. Glutathione. The thiol (-SH) group contributes to its anti-oxidative properties.
The body naturally controls the production and reduction of glutathione from its oxidized
state. In cases of severe oxidative stress, the reduction occurs too slowly for cells to
overcome the assault of ROS or RNS.

2.4.3

Hydralazine as an acrolein scavenger

Fortunately, the drug hydralazine (Figure 2.7), which is commonly used to treat
hypertension, has been found to “scavenge” for acrolein and other oxidative species.[8,
39, 45, 59, 60, 61] Particularly, the drug will scavenge and react with acrolein that has
reacted with proteins.[45] As mentioned earlier, the carbonyl group in acrolein is free for
nucleophilic attack. Once acrolein reacts with a protein, the carbonyl is free, and
hydralazine can attack it. The reaction results in a Schiff-base, imine (C=N bond)
formation, which the body uses regularly for amino acid synthesis (Figure 2.8). When the
drug reacts with free acrolein, it reduces the amount of acrolein that can induce LPO,
arresting the feed forward production of acrolein. Ultimately, stopping the process would
allow cells to recover more effectively.
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Figure 2.7. Hydralazine (left) and the imine product of acrolein and hydralazine (right).
The Schiff base on the right is the product of hydralazine scavenging acrolein and likely
to occur in a cellular environment, as similar reactions are used for amino acid synthesis.
If acrolein has already reacted with proteins, hydralazine can still react with acrolein for
removal.

Currently, hydralazine is used for hypertension. It activates a G-protein coupled receptor,
guanylate cyclase, in smooth muscle, causing a downstream signal to relax the smooth
muscle.[62] Due to this mechanism, administering hydralazine for acrolein scavenging
could critically lower an injured patient’s blood pressure. Furthermore, hydralazine has a
fairly short half-life of about 2 h in vivo, and genetic factors influence the metabolism and
side effects of the drug. Some patients who metabolize the compound quickly have been
shown to exhibit lupus-like symptoms.[63] Therefore, a therapy that could locally
concentrate hydralazine without lowering blood pressure and invading other tissues
would have great potential for SCI patients.

2.4.4

Polymeric, therapeutic molecules

Long-chain polymers have also been studied in SCI. Poly(ethylene) glycol (PEG) and
chitosan have both been studied for their effects on treating the effects of SCI and other
neurological diseases.[8, 52, 61, 64] The polymers first plug the damaged membrane by
associating with the holes. The interaction of the polymers then causes the two separated
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parts of the membrane to associate with each other, effectively closing the hole and
stopping the invasion of unwanted ions and molecules.[52, 64]

The two polymers have a few distinct differences. The molecular weight of PEG ranges
from very small (MW 250) to very large (MW 500K), depending on the application. It
also comes with a range of functional groups for different modifications or can be
modified for functionality. The applications and functionalities of PEG will be discussed
in the next section. Chitosan, on the other hand, is derived from the exoskeletons of shell
fish such as crabs and shrimp.[65] Chitin, the polymeric material from the shells, is
deacetylated in various degrees to create chitosan. Chitosan alone is not water-soluble;
therefore, it must be modified to make it water-soluble.[19] The properties of
PEG/chitosan blends have also been studied to combine the biodegradation and
biocompatibility effects of both polymers.[66, 67, 68] De Campos et al. compared
polymeric particles coated with PEG and those coated with chitosan for therapeutic
delivery to the cornea. They found that PEG had better delivery, but chitosan had a better
drug retention effect.[69]

2.4.5

Treatment Summary

A number of different molecules have been used to target the symptoms of SCI. All of
them attempt to address some, although not all, characteristic of SCI. Table 2.2
summarizes the origin and action of many of the common therapies. Table 2.3 shows the
different side effects that each therapy addresses. It is evident that a new approach is
necessary to address the complex processes that occur during and SCI.
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Table 2.2 Summary of explored, molecularly-based SCI therapies
Biological
action
Natural antioxidant

Type
Glutathione

Peptide-like
molecule

Methylprednisolone

Steroid

Immunosuppressant

Small molecule

Oxidant
scavenger;
guanylate
cyclase ligand

Hydralazine

PEG

Polymer

Membrane
sealant

Chitosan

Polymer found
in shell fish

Membrane
sealant

Biological
aspects
Increases with
cysteine uptake
Must be taken
directly after
injury; reduces
inflammation
Short half-life;
hypotension
side effect
Biocompatible;
comes in many
sizes and types
of functional
groups
Biocompatible;
must be made
hydrophilic

References
[53, 56, 58, 70]

[13, 14]

[59, 62, 63]

[8, 45, 52, 71]

[19, 64, 72, 73]

Table 2.3. Therapeutic value of SCI therapies

Glutathione
Methylprednisolone
Hydralazine
Poly(ethylene) glycol
Chitosan

Aids membrane repair
No
No
No
Yes
Yes

Anti-oxidant
Yes
No
Yes
No
No

Since the major explorations involve controlling one of the aforementioned aspects of
SCI, a therapy that could combat all of them would be a large step in helping SCI
patients. Granted, axonal regeneration is an additional factor after SCI, but oxidative
stress leads to apoptosis and necrosis. Controlling and preventing cell death is extremely
important before tissues can repair themselves. Additionally, a major problem in
inflammation is the induction of oxidative stress through cytokines. Rather than affecting
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a patient's entire immune system, it is more beneficial to locally control the inflammatory
and oxidative stress through a small scavenger like hydralazine. Decidedly, though, when
used singly, the current therapeutic approaches have limited efficiency and usage.
Ultimately, a multi-therapy and targeting approach would prove beneficial for treating
SCI.

2.5

Nanomedicine

Due to current therapeutic limitations, a nanomedical approach may help to ameliorate
poor drug availability and the biochemical effects of secondary injury. In current
therapies, drugs are administered and, hopefully, arrive at their intended location by
random chance. Nanoparticles can act as carriers and increase a therapy's circulation
time, which is critical for hydrophobic and short-lived therapies, thereby improving the
therapy's chance of reaching the cells of interest. Furthermore, biomolecules (natural or
mimetic) can be added to the nanoparticle assemblies to help with cell-uptake specificity.
After circulation and accumulation, the biomolecule hopefully increases the likelihood of
nanoparticles being internalized by the intended cells.[74] Peptides, DNA, RNA, and
receptor ligands have been used for their affinity for a particular biomarker or
characteristic, such as an increase in folate receptors on cancer cells.[75, 76, 77, 78, 79]
Unfortunately, the disease state must have a studied, reliable biomarker to target, which
may not always be the case. Without these moieties, nanoparticles may accumulate in
different areas by changing their shape or size, for instance.[80, 81] Different clearance
organs, such as the spleen, liver, and kidneys, will filter out particles based on their size.
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He et al. specifically found that smaller particles (< 200 nm) were less likely to
accumulate in the spleen and liver compared to the larger particles.[80]

Table 2.4 summarizes many of the common materials used to make nanoparticles. The
list includes inorganic material (silica and iron oxide), transition metals (gold and
quantum dots), and organic materials (chitosan, DNA, PEG). Each material harbors
certain advantages and disadvantages versus the others. Efforts have also explored hybrid
nanoparticles, merging advantages of the different materials.

Sizedependent
Surface
modificationdependent
Mixed; heavy
metal
leaching is
toxic
Low

Stober method; template
in microemulsion;
commercial sources
Thiol-based; easy, but
expensive; commercial
sources
Difficult, requires heavy
metals; expensive;
commercial sources for
color and size
Self-assembly; usually
requires modification for
assembly

Silica

Gold

Quantum Dots

Polymer (PLGA,
chitosan)

Encapsulation;
tethering

Tethering

Tethering

Adsorption;
tethering

Therapeutic
Delivery

Low

Low

Iron oxide coated with
silica
Iron oxide encapsulated
with polymer; iron oxide
requires coating due to
hydrophobicity

Silica/ Iron
Oxide

Polymer/ Iron
Oxide

Encapsulation;
tethering

Adsorption;
tethering

Combination Nanoparticles

Toxicity

Chemistry

Core Material

Table 2.4. Comparison of nanoparticle characteristics

MRI; imaging
agent

MRI; imaging
agent

Must add
imaging agent

Fluorescence

Surface
plasmon
resonance

Must add
imaging agent

Imaging

[76, 104,
105, 106,
107, 108,
109]

[20, 100,
101, 102,
103]

[67, 72, 97,
98, 99]

[91, 92, 93,
94, 95, 96]

[18, 86, 87,
88, 89, 90]

[60, 82, 83,
84, 85]
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Table 2.4 indicates that both silica and polymeric NPs provide essential features to
ameliorate the limitations of current SCI therapies, most notably their ability to adsorb
and encapsulate drugs. The distinct, overwhelming advantage silica nanoparticles provide
is the ability to form a mesoporous network. The porosity makes them especially useful
for various medical applications that include drug and gene delivery.[60, 110, 111, 112,
113] Particularly, the tunable mesoporous structure of silica networks give them qualities
of zero-order drug release.[114] The drug is released at a constant, rather than
exponential or logarithmic, rate, which could prevent side effects from high drug doses
and lower the amount of drug necessary for effective delivery. The silica encapsulates the
drug until reaching the cell or cells of interest. The method can be applied to potent
drugs, such as chemotherapy agents or environmentally-sensitive drugs.

In polymeric nanoparticles, the drugs are usually encapsulated via self-assembly.[98]
Polymeric nanoparticles are usually created via sonication or mixing that causes them to
assemble into nanostructures.[17, 115] When the nanoparticles disassemble in biological
systems, the drugs are released in a burst, which is usually the cause of adverse side
effects.[99] When therapies are released rapidly, a high local concentration can be toxic
to cells, especially in the delivery of very potent drugs (chemotherapy agents).
Avgoustakis et al. synthesized polymeric nanoparticles and in initial release, about 20%
of the anti-cancer drug cisplatin was released.[17] Zhang and Feng also had an initial
burst of the anti-cancer therapy paclitaxel of about 20%.[115] In the other types, the
therapies are usually added by a type of conjugation method, which can be limiting when
needing to deliver a small molecule.
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Various examples of using silica to deliver therapeutic molecules have been recently
demonstrated. Chauhan and co-workers have used silica hydrogels to load hydrophobic
drugs and monitor their release profile from contact lenses for glaucoma. They found
ways to change the release profile and cause release for weeks or months.[116, 117, 118,
119] The therapeutic agents can be loaded by incubating them with the porous silica.
Molecular interactions, generally Van der Waal's forces, cause the drug to adsorb on the
surface of the silica.[60, 113] Yu et al. successfully coated iron oxide nanoparticles with
silica for the purpose of protein adsorption.[103]

Silica nanoparticles can be prepared and functionalized in various ways. The starting
material, or precursor, is generally a small siloxane, such as tetramethylsiloxane (TMOS)
or tetraethylsiloxane (TEOS). Upon addition of acid or base, the precursor hydrolyzes
and eventually condenses to form the silica network at room temperature (Figure 2.8).
Although many reaction types exist, many of these stem from the Stöber method that was
published in 1968.[85] The method requires the use of a light alcohol (methanol or
ethanol) and ammonium hydroxide for catalysis.[85] A common variation on this method
includes the water-in-oil microemulsion, which uses a non-miscible solvent (alkanes) and
a surfactant.[120] Explorations of other reagents include an array of bases, solvents, and
even templates for silica nucleation. The templates are usually an organic salt, such as
cetyltrimethylammonium bromide, that creates a surfactant layer for the nanoparticles to
form in the two-solvent system. In a later step, though, the template must be removed to
create the silica shell structure. Because the template is usually a salt, it is removed using
strongly acidified alcohol, which adds an additional step to the overall synthesis. A

24
similar method for nucleation has been employed to coat iron oxide nanoparticles with
silica.[20] Depending on the various reaction conditions, the pore size, surface area, size,
and shape of the nanoparticles will change.[84, 121, 122, 123, 124] Starting material
concentration, catalyst concentration, and the solvent system also play an important role
in the silica formation.[2, 121]
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Figure 2.8. Formation of silica network with TMOS precursor. A silica precursor (often
TMOS or TEOS) undergoes hydrolysis in the presence of an acidic or basic catalyst
followed by condensation with another hydrolyzed silica precursor molecule. The
formation and size of size of silica nanoparticles is dependent on precisely controlling the
rate of both steps.

Different functional groups can be introduced on the surface of the silica by adding an
additional precursor with a functional group of interest, which is known as the cocondensation method. Using this method, the functionality and application of silica
nanoparticles has greatly improved. The organosiloxane is introduced in the original
mixture or grafted onto the nanoparticles in a later reaction. In grafting reactions, it is
possible that the functional groups will become part of the silica network or nucleate,
creating new nanoparticles.[124, 125] Therefore, not only does grafting create a separate
step in the synthesis of the nanoparticles, but it may also create diverse populations of
nanoparticles in one mixture. This adds both time and cost to the overall process if the
nanoparticles must fit within a defined range of criteria. Otherwise, organosiloxanes
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come with a variety of groups, such as carboxylic acids, amines, and polymers, which are
especially useful for biological tethering.

PEG is a biocompatible polymer that is commonly used for a “stealth” layer on
nanoparticles.[2, 126, 127, 128, 129] PEG prevents protein adsorption on the surface of
nanoparticles during circulation (opsonization), which “hides” the nanoparticles from
attack by immune cells. It can be combined with silica to improve aqueous stability,
retention, and reduce toxicity both in vivo and in vitro.[1, 127, 129, 130] Similar to other
reaction conditions, even the amount of PEG seems to affect the size of silica
nanoparticles.[127] Similar to organosiloxanes, PEG is available in numerous sizes and
may have a number of functional moieties for various applications. Furthermore, PEG
provides additional targeting for both localization and therapy for SCI applications. A
local injection of PEG helped to alleviate systems of oxidative stress in neuronal cells by
aiding in repairing damage to the membrane.[52]

Cytotoxicity has been a concern with silica nanoparticles, though. Studies with them have
found that both very small and very large nanoparticles tend to create toxicity problems.
On the other hand, nanoparticles in the sub-micron range (50-300 nm) exhibit a lower
toxicity.[82, 83, 131] In in vivo studies, there are mixed results. Table 2.5 shows a few
highly-cited studies on silica nanoparticle toxicity. For comparison purposes, it only
highlights single-dose toxicity studies in mice. Hudson and co-workers found their
nanoparticles to be the most toxic using both intraperitoneal (IP) and intravenous (IV)
injections. Based on the characterization of their nanoparticles, their results seem to be
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attributed to the dose and size of their nanoparticles. Although all the studies used both
dynamic light scattering (DLS) and electron microscopy (EM) to confirm and corroborate
their size results, Hudson and co-workers had a disparities among the size of
nanoparticles for each method.

Dynamic light scattering measures the radius a particle appears to have in solution.
Components of a solvent or buffer form a layer that moves with the nanoparticle, forming
the hydrodynamic radius. As a particle moves through solution (Brownian motion), it
scatters light that can be collected. A large particle moves more slowly and scatters less
light while a smaller particle moves more quickly in comparison.[132] Obviously, since
the particles are moving in a fluid, the solvent properties, specifically viscosity, changes
their motion in the fluid system. In EM, the particles are dried and may be sputtered
before being imaged, which can cause aggregation.[133] Therefore, DLS is likely a truer
measurement of how the silica nanoparticles behave in a fluid, biological system. Hudson
et al. had very large particles (470 nm ± 252) based on DLS measurements while SEM
showed particles of only 100-150 nm. In their preparation for DLS, they described that
the samples were sonicated and vortexed for two hours prior to the measurement, which
is a good indication that their particles were probably both large and aggregated if such
forces were needed to separate them. Furthermore, they mentioned that even after
preparation, the particles would fall out of suspension.[134] The size of the particles,
coupled with the large dose, likely contributed to the erratic behavior and mortality of the
mice. Granted, both Hudson et al. and Liu et al. found that high doses (>1000 mg/kg) of
the nanoparticles had some toxic effects.
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Table 2.5. In vivo studies of silica nanoparticle toxicity
Type

Hudson et
al.[134]
Hudson et
al.[134]

Mesoporous
silica with
PEG
Mesoporous
silica
Mesoporous
silica

Size (nm)
TEM: 80, 120,
200, and 360
DLS: little larger
TEM: 80, 120,
200, and 360
DLS: little larger
SEM: 100-150
DLS: 470
SEM: 100-150
DLS: 470

Liu et
al.[135]

Mesoporous
silica

DLS and TEM:
110

He, Q et
al.[80]
He, Q et
al.[80]

Mesoporous
silica

2.6

Dose

Toxicity

20 mg/kg IV

No toxicity; no
pathological changes

20 mg/kg IV

No toxicity; no
pathological changes

30 mg IP
(1200 mg/kg)

Died within 24 hours

6 mg IV
40, 160, 500,
1000, and 1280
mg/kg IV

Died within 15
minutes
No death until 1000
mg/kg; Some
pathological changes

Integrating neurological disease and nanomedicine

A few efforts have been made to incorporate nanotechnology and SCI. Specifically, Cho
et al. synthesized silica nanoparticles to deliver hydralazine to healthy cells that had been
exposed to acrolein.[60] They used a template-based synthesis of their silica
nanoparticles, grafted an additional silica layer, and attached a PEG layer. In the end, the
particles were around 126 nm. They were able to deliver hydralazine to PC-12 cells (rat
neurons) over a period of five days in vitro but not in a linear fashion. The bulk of the
drug was released in the first few hours. Based on numerous cell assays that measure cell
viability and therapeutic activity, they concluded that their nanoparticles were able to
rescue the neurons without inducing further toxicity. In a separate study, they used
similar nanoparticles ex vivo after crushing the spinal cord.[136] The particles did not
contain hydralazine for acrolein scavenging and appeared to recover their ability to
conduct action potentials nearly to the pre-crush level. They speculate that the recovery
originated from the PEG coating on the outside of the nanoparticles.
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Later, they attempted to use chitosan-based nanoparticles to study acrolein scavenging.
Hydralazine was encapsulated by the assembled nanoparticles, which had a diameter of
around 350 nm. They found that the chitosan nanoparticles had lower encapsulation
efficiency, but they were still able to decrease the death of healthy cells exposed to
acrolein.[72] Yet Tysseling-Mattiace et al. used self-assembling peptides to try to
promote axonal regeneration after SCI. Their mice improved in motor capabilities and
they found decreased apoptosis in and around the injury site.[137] Again, these
approaches address some of the SCI problems and show promise of using a nanomedical
approach, but it can be improved.
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CHAPTER 3. AIM 1: DESIGN, SYNTHESIZE, AND CHARACTERIZE HYBRID
SILICA NANOPARTICLES

3.1

Introduction

There are various ways to create silica nanoparticles. [60, 126, 127, 130, 138] A rather
simple synthesis that eliminates the need to graft or add PEG in a later step involves the
co-condensation of PEG with the starting siloxane, which has been demonstrated.[1, 2]
The "stealth" polymer, generally designed to prevent the deposit of proteins on its surface
to minimize interactions with the immune system and increase circulation time, must be
conjugated to a functional group present in the original nanoparticles or grafted via
electrostatic interactions. In the former schemes, an additional organosiloxane, generally
containing an amine or carboxylic acid derivative, is added with the precursor (TMOS or
TEOS) to functionalize the nanoparticles. The PEG, functionalized with a reactive
moiety, is then conjugated to the nanoparticles.[126] The PEG content relies on the
functionalization with the organosiloxane, and depending on whether the organosiloxane
modification occurs during or after initial particle formation, the synthesis requires two to
three steps. With PEG grafting, the PEG coats the nanoparticles via electrostatic
interactions.[130, 138] Over time, the PEG may dissociate from the silica nanoparticles,
or the coatings may become uneven. In the current study, the PEG serves a dual purpose.
PEG is nanomedicine's "stealth" molecule, as it has been shown to prevent
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opsonization.[18, 129] Specifically for spinal cord injury, PEG serves as a target for
injured neurons and associates with them, aiding in membrane repair.[52]

3.2
3.2.1

Materials and methods

Synthesis of mPEG-amine silica nanoparticles

The silica nanoparticles were synthesized using a modified Stöber method.[2, 85] 20 mg
of amine- modified methoxy poly(ethylene) glycol (mPEG-Am) MW5000 (0.004 mmol)
(Sigma, St. Louis) was dissolved in 6 mL of methanol. Upon dissolution, 64 uL of
tetramethylorthosilicate (0.434 mmol) (TMOS, Sigma, St. Louis) was added. Drop wise,
750 uL of 2 M NaOH (1.5 mmol) was added to the mixture while agitating. The solution
was vortexed at 25°C for 1 hour. To remove most of the solvent, the milky solution was
added to a 30 kDa Amicon membrane filter (Millipore, Billerica, MA) and centrifuged
for 15 minutes at 2800 g. The filtrate was removed, and 5 mL of nanograde water was
added to the filter and spun again for 10 minutes. The solution was aged for 15 days
before 3 mL of nanograde water was added to the filter and spun for 15 minutes. Residual
methanol was removed via evaporation. Concentration of the nanoparticle solution was
obtained gravimetrically by solvent evaporation under vacuum. For use in cell culture,
the nanoparticle samples were sterile filtered using a 0.2 µm syringe filter and diluted to
appropriate concentrations in phosphate buffered saline (PBS).

3.2.2

Synthesis of PEG-hydrazide silica nanoparticles

Synthesis proceeded as described for mPEG-Am nanoparticles. mPEG-hydrazide
MW5000 (mPEG-Hz) was obtained from Laysan Bio, LLC (Arab, AL).
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3.2.3

Size measurements and stability

The dynamic light scattering (DLS) of nanoparticles was measured in both nano-grade
water and PBS using a Zetasizer NS (Malvern, United Kingdom) at 25°C and 37°C. Each
measurement was taken four times to create an average result. The polydispersity index
(PDI) of the nanoparticles was also determined to avoid conditions where the
nanoparticles would aggregate. For stability measurements, the samples were stored at
25°C and measured at various time points. Upon loss of volume, 200 uL of the
appropriate solvent (water or PBS) was added to the sample before measuring.

3.2.4

Zeta potential

The interaction of all particles in aqueous media is governed by the “zeta potential” of
both the cells and the nanoparticles. The nanoparticles were measured in both nano-grade
water and PBS at pH 7 using a Zetasizer NS (Malvern, UK) at 25°C and 37°C. Each
measurement was taken three times to create an average result. Since zeta potential
includes the particle-associated counter-ions attracted to the particle or cell from the
medium, the zeta potential will be different in water versus PBS.

3.2.5

Fourier Transform Infrared (FTIR) infrared spectroscopy

As synthesized nanoparticle samples were previously suspended in nano-grade water.
Amine-terminated methoxy PEG was dissolved in nano-grade water. Ten uL of
nanoparticle or PEG solution was placed onto a crystal KBr card (International Crystal
Laboratories, NJ) and allowed to dry. Before running samples, a water background was
obtained. Each spectra was obtained with 256 scans on a Nicolet FTIR (Thermo
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Scientific) and processed using KnowItAll Informatics System (Bio-Rad). The FTIR
spectra were used to examine specific bond arrangements important to the correct overall
assembly of the nanoparticles and conjugated molecules.

3.2.6

Reflective hyperspectral imaging

Samples for reflective hyperspectral imaging (RHI) were sent to Cytoviva, Inc in Arab,
AL. For PEG modification on the nanoparticles, nanoparticles with and without PEG
were sent for spectral analysis, along with PEG alone. The spectra were compared and
both silica nanoparticles and PEG were mapped in the PEGylated nanoparticle sample.
RHI, unlike electron microscopy techniques, can be done on samples in an ambient
environment rather than dry, vacuum conditions. Samples that are not electron dense can
also be imaged using this technique.

3.3
3.3.1

Results and discussion

Synthesis of mPEG-Am nanoparticles

The silica nanoparticles were prepared to incorporate the polymer into the silica network,
which eliminates an additional PEGylation step that is common in many other synthesis
schemes. In the one-step synthesis, the PEGylation is a function of its hydrolysis and
condensation with the siloxane (Figure 3.1). Furthermore, the Stöber method creates
water and alcohol as by-products, eliminating the need to remove the organic solvents
and surfactants in emulsion techniques. Volatile alcohols are fast and easy to remove.
Inorganic surfactants used to synthesize silica nanoparticles require harsh, acidic
environments to remove them from the surface of the silica nanoparticles.[121, 133, 139]
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Ma et al. reported a synthesis technique using a combination of the Stöber and
emulsification methods.[140] The synthesis and purification was performed at 30°C and
utilized a surfactant with an alcohol and water solvent system. Especially for use in
biological systems and scaling procedures, eliminating side products and steps may make
production much faster, easier, and cheaper.
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Figure 3.1. Synthesis scheme of Si-mPEG NP's. The silica precursor, TMOS, is
hydrolyzed and condensed with methoxy-PEG and TMOS. Condensation with TMOS
allows the nanoparticle network to grow whereas condensation with mPEG stops the
growth of the particle.

3.3.2

FTIR analysis of mPEG-Am nanoparticles

To confirm the synthesis technique, the nanoparticles were analyzed using Fourier
transform infrared spectroscopy (FTIR). The technique relies on the vibration of chemical
bonds in a sample using IR. It can be used to compare samples based on the formation or
disappearance of particular bonds and/or functional groups in the different samples. In
this study, unmodified nanoparticles and mPEG alone were analyzed and compared to
mPEG-containing nanoparticles (Figure 3.2). In the plain nanoparticles, silica ester bonds
are shown the 1300-1000 cm-1 region and the same peak appears in the PEGylated
sample, but it has broadened and contains shoulders from the fingerprint region (900-800
cm-1) of the PEG. Lastly, a weak, broad band has appeared around 2900 cm-1 of the
PEGylated sample, which is indicative of C-H stretching.
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Figure 3.2. FTIR spectra of (top left) Non-PEGylated nanoparticles, (top right) mPEGamine, and (bottom) mPEG-amine nanoparticles. The bare nanoparticles show
characteristic peaks of silica-ester bonds in 1200 cm-1 region, which overwhelms the
smaller peaks of the mPEG-Am alone on the PEG-modified nanoparticles. The
PEGylated nanoparticles show a slight broadening in the ester region (1300-1000 cm-1),
which is indicative of Si-O-C bonds after condensation during synthesis.

3.3.3

Reflective hyperspectral imaging of mPEG-amine nanoparticles

To corroborate the FTIR data, samples were sent to Cytoviva, Inc. for reflective
hyperspectral imaging. To obtain a spectrum, the technique relies on collecting the
reflected light from a sample to show spatial co-association of different molecules. For
the analysis, PEG and nanoparticles with and without PEG were analyzed (Figure 3.3).
From there, the PEGylated sample was analyzed and using the control spectrum,
"mapped" for the presence of PEG and silica nanoparticles (Figure 3.4). The PEGylated
sample shows the presence of PEG and silica juxtaposed. The spectrum of each sample is
also different. In the PEGylated sample, the spectrum has shifted towards the peak of the
PEG sample, indicating a change in the reflectance pattern of the sample that could be
attributed to the presence of PEG.
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Figure 3.3. Hyperspectral maps of mPEG alone (left), non-PEGylated sample (right) and
Si-mPEG sample (middle). The PEGylated sample shows a shift towards the mPEG
spectra that may be attributed to PEG. Images provided by Cytoviva, Inc. (Arab, AL).
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Figure 3.4. Mapping of mPEG and silica nanoparticles on a pixel by pixel basis. The
presence of PEG was confirmed after the synthesis of the nanoparticles. Images provided
by Cytoviva, Inc. (Arab, AL).

3.3.4

Characterization of mPEG-Am nanoparticles

The synthesized nanoparticles were collected and measured using dynamic light
scattering (DLS). Specifically for nano-type applications, size, stability, and zeta
potential are all important characteristics. Therefore, determining these characteristics are
important if the nanoparticles are to be used clinically. For instance, the body has natural
size and charge (zeta potential) filters, including the kidneys, liver, and spleen. Each of
these organs will remove particles of various sizes and charges, and in order for the
nanoparticles to be effective, they should be tailored to fall within a range that avoids
excessive uptake by these organs.[80]
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Dynamic light scattering (DLS) measures the radius a particle appears to have in solution.
Components of a solvent or buffer form a layer that moves with the nanoparticle, forming
the “hydrodynamic radius”. As a particle moves through solution (Brownian motion), it
scatters light that can be collected. A large particle moves more slowly and scatters less
light while a smaller particle moves more quickly in comparison. Based on DLS
measurements, the nanoparticles have an average hydrodynamic diameter of 21.33 nm
and a polydispersity index (PDI) of 0.085, indicating a small range of sizes in the
population (Figure 3.5). The PDI gives an indication of a sample's population
distribution, ranging from 0.00-1.00. A high PDI usually indicates various size
populations in one sample. The samples were stored at room temperature in the sample
cuvette and measured over time. Even after long periods of time, the nanoparticles retain
their integrity. They can also be diluted into PBS and retain their integrity, but they begin
to aggregate after only six months.

38

Figure 3.5. DLS size of mPEG-Am NP's in aqueous solution after synthesis and after 42
weeks (10 months) of shelf storage. The sample was pulled directly after synthesis and
filtered through a 0.2 um. Subsequent measurements were taken of the same sample over
time.

Directly after removing the organic solvent, the pH of the nanoparticle solutions is about
10 from the base catalyst. The nanoparticles are stable in the solution, but for biological
purposes, the pH must be adjusted. To account for this change, the particle solutions were
diluted, pH-adjusted, and their properties were measured at a neutral pH in both water
and PBS.

Zeta potential deals with how the nanoparticles arrange charges in a solution, which can
affect how the nanoparticles will interact with cells. It may affect the pathway the
nanoparticles undergo. On the other hand, they could either stick heavily to the cell
membrane or be repelled by the charge arrangements. Zeta potential also gives an
indication of how the nanoparticles interact with each other. A neutral, or zero, zeta
potential indicates instability and association of the nanoparticles with each other, which

39
usually leads to aggregation –something highly undesirable, especially in clinical
applications.

Table 3.1. Size and zeta potential of mPEG-Am nanoparticles
Temp.
(ºC)

Solution

Diameter
(nm)

PDI

Zeta Potential
(mV) (St. Dev.)

25
25
37
37

Water
PBS
Water
PBS

24.78
24.19
24.07
23.28

0.147
0.121
0.131
0.129

-29.2 (1.7)
-25.0 (2.3)
-26.2 (1.1)
-21.9 (0.8)

Zeta of NonPEG sample
(mV)
-31.7 (6.9)
-25.4 (1.2)
-29.3 (0.7)
-23.4 (0.8)

The PDI increases once the pH has been adjusted, which is likely due to a change in both
the ionic strength and pH (Table 3.1). In more acidic conditions, the positively charged
hydrogen ions are attracted to the negatively charged surface of the nanoparticle
becoming part of the associated counter-ion cloud and slightly lowering the zeta
negativity of the zeta potential. The zeta potential is negative, likely due to the various
silanol groups on the surface of the nanoparticle. To prevent non-specific sticking of the
nanoparticles to the cells, which are almost always negatively charged with a zeta
potential of approximately 10-20 mV, the nanoparticles should be at least slightly
negatively charged zeta potential of about -5 to -10 mV, Targeting molecules, in this
case the attraction of PEG for cell membrane lipids, will overcome a slight electrostatic
barrier between the nanoparticles and the cells to produce a good targeting effect to
injured cells. The PEG creates a shielding effect, which changes with the temperature and
ionic strength. For instance, polymer interactions often change with temperature, and
those changes are mostly absent in the non-PEGylated sample. The effect of the solution
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is seen less at room temperature, but at body temperature, the zeta potential increases in
both water and PBS, which may be accounted for in the ion concentration difference
between water and PBS. PBS contains more ions to create a plane around the
nanoparticles, offsetting the high negative charge. The PEGylated sample also has a low
ratio of amine groups that can contribute to changing the charge around the particle,
which is not present in the non-PEGylated sample.

3.3.5

Characterization of mPEG-Hz nanoparticles

The hydrazide nanoparticles have a particular advantage not present with the aminemodified nanoparticles. The active group of hydralazine is an azine, or R-NH-NH2 off an
aromatic phthalazine, and its hypertension activity stems from the phthalazine. The
mPEG-hydrazide contains a similar group, but the aromatic part has been replaced by
PEG and a carbonyl (C=O) in the R position of R-NH-NH2. This may help the reactivity
of the azine, as the carbonyl withdraws electrons from the azine, making it more
nucleophilic. Because its reactivity is higher than that of amine groups, hydrazides are
often used for bioconjugations. Therefore, the hydrazide group on the end of the mPEG
may actively scavenge acrolein without the need for drug loading and possible side
effects from using hydralazine.

Similar to the amine-modified nanoparticles, after synthesis, the hydrazide-modified
nanoparticles were measured using dynamic light scattering (Figure 3.6). The
nanoparticles have an average initial size of 20.26 nm in diameter with a PDI of 0.071.
After storing them for over six months, they continue to be stable in solution.
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Figure 3.6. DLS size of mPEG-Hz NP's both after synthesis and 30 weeks (6.5 months)
of storage at room temperature. The nanoparticles have a narrow size distribution and
retain their integrity over time.

Similar to the mPEG-Am nanoparticles, the mPEG-Hz nanoparticles remain stable for
long periods of time in the basic pH, but their size and zeta potential were measured in
water and PBS at pH 7 (Table 3.2). The hydrazide-modified nanoparticles have a higher
zeta potential than their amine-modified counterparts, more than likely due to the
increased amine groups on the end of the hydrazide PEG.

Table 3.2. Size and zeta potential of mPEG-Hz nanoparticles.
Temp.
(ºC)
25
25
37
37

Solution
Water
PBS
Water
PBS

Diameter
(nm)
23.00
28.33
22.49
26.24

PDI
0.128
0.281
0.149
0.192

Zeta Potential (mV)
(St.Dev)
-29.5 (4.8)
-22.2 (2.0)
-22.3 (2.4)
-21.4 (1.6)

Zeta of Non-PEG
sample (mV)
-31.7 (6.9)
-25.4 (1.2)
-29.3 (0.7)
-23.4 (0.8)
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3.4

Concluding summary

This particular aim of the project focuses on the synthesis and characterization of the
silica-based nanoparticles. This work demonstrates the feasibility of producing
silica/polymer nanoparticles with a narrow size distribution using a facile synthesis
scheme. Additional discussion can also be found in the reference by White-Schenk et al.
(2013).[141]
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CHAPTER 4. AIM II: EVALUATE THE TOXICITY OF HYBRID NANOPARTICLES
IN VITRO.

4.1

Introduction

In order for nanomedicine to be clinically relevant, it is imperative that the nanoparticles
themselves do not induce stress or harm to healthy or injured cells. The nanoparticles
may induce damage through various pathways. They may cause oxidative stress,
necrosis, or induce apoptosis, which are important to distinguish.

4.2
4.2.1

Materials and methods

B35 rat neuroblastoma cell culture

B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture
Collection) and cultured in T-25 or T-75 flasks with DMEM (Sigma) supplemented with
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in
concentrations from 1:4 to 1:8. For all experiments, cells were used in the log phase of
growth.

4.2.2

C8-B4 mouse glioblastoma cell culture

C8-B4 mouse glioblastoma cells were obtained from ATCC (American Tissue Culture
Collection) and cultured in T-25 with DMEM (ATCC) supplemented with 10% FBS
(Invitrogen). The cells were co-cultured upon at least 80% confluency (7-14 days) and
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seeded at concentrations no less than 1x105 cells/mL. For all experiments, cells were used
in the log phase of growth.

4.2.3

Lactate dehydrogenase (LDH) assay for nanoparticle toxicity

LDH activity gives a measure of cell's membrane integrity. As the membrane is damaged,
cytosolic LDH is released from the cell. The LDH Toxicology Kit was purchased from
Sigma and used per the manufacturer's instructions. B35 cells were seeded in triplicates
at 5 x 105 cells/mL in DMEM with 10% FBS overnight. The cells were incubated with
nanoparticles in complete growth medium for 24 hours before analyzing the growth
medium for LDH activity. To determine the total LDH amount, a set of untreated cells
were lysed using 0.5% Triton-X. The LDH activity was measured using a VersaMax
microplate reader (Molecular Devices, LLC, Sunnyvale, CA). The data is reported as a
change of LDH activity compared to the lysed control wells, calculated as follows:

4.2.4

Oxidative stress analysis by LEAP

Dihydroethidium is a compound that, once activated by reactive oxygen species,
integrates with DNA and fluoresces red. To determine oxidative stress or DNA damage
caused by the nanoparticles, B35 cells were seeded overnight in a Cyntellect LEAP plate
at 5 x 105 cells/mL (2500 cells/well in 384-well plate) in DMEM with 10% FBS. Varying
concentrations of nanoparticles in PBS or vehicle was added to the cells and incubated
for 24 hours. 150 uM of acrolein and 150 uM hydrogen peroxide were used as positive
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controls for oxidative stress. Before running the experiment, the optimal dye
concentration was determined using untreated cells and cells treated with the positive
controls. After 24 hours, the cells were washed with PBS three times, and they were
incubated in 10 uM DHE for 30 minutes. The excess dye was washed away, and the cells
were analyzed in DMEM with 10% FBS and 5 ug/mL Hoechst 33342 using Cyntellect's
Laser-Enabled Analysis and Processing (LEAP) image cytometer. The analysis settings
were optimized using the positive and negative controls before obtaining data from all
samples. The data was exported for post-processing in Excel. Images were processed
using ImageJ (NIH, Bethesda, MD). C8-B4 cells were seeded at 2x105 cells/mL (2000
cells/well in 384-well plate) and processed similarly for toxicity experiments.

4.2.5

Cytotoxicity analysis by LEAP

To determine specific viability of the cells after nanoparticle incubation, B35 cells were
seeded overnight in a Cyntellect LEAP plate at 5 x 105 cells/mL in DMEM with 10%
FBS. Varying concentrations of nanoparticles in PBS or vehicle was added to the cells
and incubated for 24 hours. 150 uM of acrolein was used as a positive control. Before
running the experiment, the optimal dye concentrations were determined using untreated
cells and cells treated with the positive control. After 24 hours, the cells were washed
with PBS three times, and they were incubated in 2 uM calcein am green for 30 minutes.
The excess dye was washed away, and the cells were analyzed in DMEM with 10% FBS
and 5 ug/mL Hoechst 33342 using LEAP. The analysis settings were optimized using the
positive and negative controls before obtaining data from all samples. The data was
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exported for post-processing in Excel. C8-B4 cells were seeded at 2x105 cells/mL (2000
cells/well in 384-well plate) and processed similarly for toxicity experiments.

4.2.6

Near-infrared fluorescent (NIRF) labeling of nanoparticles

As synthesized nanoparticles were vortexed with 1:10 molar ratio of CF 680:PEG
(Sigma, St. Louis) for 2 hours in the dark before undergoing dialysis overnight to remove
unreacted dye.

4.2.7

Nanoparticle uptake by confocal microscopy

B35 cells were seeded overnight at 5 x 105 cells/mL in 35 mm Fluorodishes. Vehicle or
350 ug/mL nanoparticles in PBS was added to the cells and incubated for 24 hours. After
the incubation period, the cells were washed three times with PBS, and the cells were
fixed in 4% paraformaldehyde (PFA) for 25 minutes and subsequently washed three
times. They were permeabilized with 0.1% Triton X-100 for 5 minutes and washed
before staining with 5 uL of phalloidin Alexa Fluor 488 (Invitrogen) in 1% blocking
buffer for 30 minutes. In the last ten minutes, 300 ng/mL propidium iodide (PI,
Invitrogen) was added as a counterstain. The excess dye solution was removed, and
Vectashield was added to the dishes.

Confocal images were obtained using and Olympus Fluoview at 20X set with the
appropriate filters for Alexa Fluor 488 using a 488 nm laser, PI using a 543 nm laser, and
Cy5.5 using a 633 nm laser. Images were exported for analysis using ImageJ.
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4.2.8

Oxidative stress analysis by LEAP in co-culture model

To determine oxidative stress or DNA damage caused by the nanoparticles, B35 and C8B4 cells were seeded overnight in a Cyntellect LEAP plate at 1.4 x 105 cells/mL and 6 x
104 cells/mL (1680 cells/well and 720 cells/well in 384-well plate), respectively, in
DMEM with 10% FBS. Therefore, about 30% of the original population of each sample
was C8-B4 cells, optimized before the experiment. Additional wells using only B35 cells
and C8-B4 cells were also seeded at 2x105 cells/mL (2400 cells/well). Varying
concentrations of nanoparticles in PBS was added to the cells and incubated for 24 hours.
200 uM hydrogen peroxide was used as positive control for oxidative stress. Before
running the experiment, the optimal dye concentration was determined using untreated
cells and cells treated with the positive controls. After 24 hours, the cells were washed
with PBS twice, and they were incubated in 10 uM DHE for 30 minutes. The excess dye
was washed away, and the cells were analyzed in DMEM with 10% FBS and 10 ug/mL
Hoechst 33342 using LEAP. The analysis settings were optimized using the positive and
negative controls before obtaining data from all samples. The data was exported for postprocessing in Excel. Images were processed using ImageJ (NIH, Bethesda, MD).

4.2.9

Cytotoxicity analysis by LEAP in co-culture model

To determine specific viability of the cells after nanoparticle incubation, B35 and C8-B4
cells were seeded overnight in a Cyntellect LEAP plate at 1.5 x 105 cells/mL and 5 x 104
cells/mL (1680 cells/well and 720 cells/well in 384-well plate), respectively, in DMEM
with 10% FBS. Therefore, about 30% of the original population of each sample was C8B4 cells, optimized before the experiment. Additional wells using only B35 cells and C8-
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B4 cells were also seeded at 2x105 cells/mL (2400 cells/well). Varying concentrations of
nanoparticles in PBS or vehicle was added to the cells and incubated for 24 hours. Before
running the experiment, the optimal dye concentrations were determined using untreated
cells and cells treated with the positive control. After 24 hours, the cells were washed
with PBS twice, and they were incubated in 2 uM calcein am green for 30 minutes. The
excess dye was washed away, and the cells were analyzed in DMEM with 10% FBS and
10 ug/mL Hoechst 33342 using LEAP. The analysis settings were optimized using the
positive and negative controls before obtaining data from all samples. The data was
exported for post-processing in Excel.

4.2.10 Statistical analysis
To determine statistical significance, ANOVA was performed on each data set. For pairwise comparisons, a test using the Least Significant Difference (LSD) was used. P-values
less than 0.01 were considered significant.

4.3
4.3.1

Results and discussion

LDH assay for nanoparticle toxicity

An additional important factor in using a nanoparticle-based delivery system is the
potential toxicity of the delivery system. Particularly for silica nanoparticles, some
studies have shown cytotoxic effects. Because a neuron's membrane is essential to its
function, the lactate dehydrogenase activity assay was chosen to measure toxicity. As the
membrane integrity of the cells are compromised, the protein escapes from the
cytoplasm. Therefore, higher activity indicates a higher level of membrane damage in the
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cell population. Triton X-100 was chosen as the positive control, and the cells within
those wells had lysed after the incubation period. The LDH activity is measured relative
to the lysed cells as described in the methods (Figures 4.1 and 4.2). Even at high
concentrations, the nanoparticles did not adversely affect the cells' membrane integrity.

mPEG-Amine Toxicity after 24 h in B35 cells
110
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Percent of LDH release

80
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0.5% Triton 50 ug/mL
X-100

100 ug/mL 200 ug/mL 300 ug/mL 400 ug/mL 500 ug/mL

Figure 4.1. Membrane integrity measurement by LDH in B35 cells incubated with
mPEG-amine nanoparticles for 24 hours. None of the concentrations showed significant
damage from the control (P > 0.01).

After 24 hours, the nanoparticles did not induce significant damage to the cells. Even at
high concentrations, the cells' membranes remained intact. Upon microscopic
examination, the cells maintained their morphology, including dendrite-like processes
(data not shown), rather than rescinding their processes and changing cell body
morphology. Because the LDH assay is limited to looking at the entire cell population
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rather than single cells, though, it is limited in its scope. Therefore, it is imperative to
corroborate its results with other, more sensitive assays.

LDH Assay of mPEG-Hz nanoparticle toxicity in B35 cells after 24 h
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Figure 4.2. Membrane integrity measurement by LDH in B35 cells incubated with
mPEG-hydrazide nanoparticles for 24 hours. None of the concentrations showed
significant damage from the control (P > 0.01).

4.3.2

Reactive oxygen species (ROS) generation

To overcome the weakness of the LDH assay, dihydroethidium (DHE) was used to
monitor cells that were incubated with nanoparticles. After incubation, the nanoparticles
were removed, and the cells were stained with DHE and Hoechst. DHE reacts with ROS
and upon intercalation with DNA, it has a red emission spectra. Laser-scanning
cytometry via LEAP counts and records the characteristic for each cell, giving a detailed
view of each cell's behavior, which can be compiled.
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ROS production: mPEG-Am nanoparticles
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Figure 4.3. ROS production from mPEG-amine nanoparticles measured via
dihydroethidium (DHE) fluorescence and analysis by LEAP. Nanoparticles were
incubated for 24 hours. None of the concentrations showed significant damage from the
control (P > 0.01).

Similar to the LDH assay, the results using DHE show very little oxidative stress induced
by the mPEG-amine nanoparticles (Figures 4.3 and 4.4). More than likely, their small
size and the outer layer of PEG prevents an adverse reaction to the nanoparticles.
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ROS-production: mPEG-Hz nanoparticles
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Figure 4.4. ROS production from mPEG-hydrazide nanoparticles measured via
dihydroethidium (DHE) fluorescence and analysis by LEAP. Nanoparticles were
incubated for 24 hours. None of the concentrations showed significant damage from the
control (P > 0.01).

For comparison, images of control wells and nanoparticle wells are shown in Figure 4.5.
Even at the high concentrations, the nanoparticles did not induce oxidative stress, which
is important if they are to be used for targeting oxidative stress in clinical applications.
The cell number in the acrolein sample had obviously dropped drastically, and nearly half
of the cells were DHE-positive. Additionally, it is interesting to note the extensive
damage acrolein causes to the cells when compared to the same concentration of
hydrogen peroxide.
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Figure 4.5. Representative nanotoxicity LEAP images. Cells were incubated for 24 hours
with various compounds and stained with Hoechst 33342 (blue) and DHE (red).

4.3.3

Cell viability after nanoparticle incubation

To look at toxicity further, viability was determined using calcein AM, a live-cell dye,
and Hoechst 3342, a nucleic acid dye for a total cell count. The cells were incubated with
the corresponding nanoparticles for 24 hours and stained with the two dyes for analysis
with LEAP.
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Nanotoxicity: mPEG-Am nanoparticles
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Figure 4.6. Cell viability and cell number of B35 cells after being exposed to mPEGamine nanoparticles for 24 hours. The samples with nanoparticles do not show a
significant decrease in viability. The cell number also remains consistent. (mean ± SE; P
> 0.01)

Like the previous experiments, the mPEG-amine nanoparticles showed no significant
change in viability after the 24-hour period, even at the highest concentrations (Figure
4.6). The nanoparticles also did not affect the viability of the neuronal cells. More
importantly, though, the cell population was consistent with the untreated cells.
Oftentimes, a high viability may be seen in a whole cell population, but likely these cells
have undergone "survival of the fittest" since missing cells may simply disappear through
apoptosis or violent, explosive necrosis. It is crucial to ensure that the cell population is
not only healthy but also still present to prevent such artifacts in experiments. Different
results were seen with cells incubated with mPEG-Hz nanoparticles (Figure 4.7).
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Nanotoxicity: mPEG-Hz nanoparticles
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Figure 4.7. Cell viability and cell number of B35 cells after being exposed to mPEGhydrazide nanoparticles for 24 hours. The samples with nanoparticles do not show a
significant decrease in viability. The cell number slowly decreases with an increase in
concentration, though, indicating a change in cell health and growth. (mean ± SE; *P <
0.01)

The cell viability does not decrease, but the cell number steadily drops as the nanoparticle
concentration increases. The drop becomes significant in the cells incubated with 400
ug/mL of nanoparticles. The cell growth may be stifled from the large quantity of
nanoparticles, or, in a more likely case, they are dying. If they undergo apoptosis, their
contents will be packaged and exported, or death via necrosis may cause the cells to
essentially "explode;" both cases would account for a decrease in cell number without
adversely affecting the overall viability, as one cannot count what is not present. The
drop becomes significant in the cells incubated with both 400 ug/mL and 500 ug/mL of
nanoparticles. In those samples, the cell population is healthy, but its population was
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stifled. The high viability of the 500 ug/mL sample exemplifies seeing a high viability
number merely from the hardiest cells surviving, and demonstrates the importance of
single-cell analysis techniques.

A possible explanation for the difference in the cell response to the two different
nanoparticles likely stems from the difference in the two PEG products. The products are
from two different manufacturers with different methods of PEG modification and
purification. Upon first adding the hydrazide nanoparticles to the cells, the aggregate in
the media so much that it can be seen under low magnification. The mPEG-Am
nanoparticles and lower concentrations of mPEG-Hz nanoparticles does not have the
same effect. Beyond that, hydrazides are often used for their "click" chemistry
capabilities. At high levels of the nanoparticles, it could possibly interfering with
membrane proteins or signaling. Regardless, the amount of nanoparticles used in the
experiment are unrealistically high levels for the amount of cells (7.5 ug nanoparticles per
5000 cells at the highest concentration).

4.3.4

Nanoparticle uptake via confocal microscopy

For the purpose of delivery, it is important that the nanoparticles affiliate with the cells of
interest. In an in vitro setting, the cells are incubated with the nanoparticles for a period
of time and the cells are explored for the presence of nanoparticles. In this study,
nanoparticles were labeled with a near-infrared fluorescent (NIRF) dye similar to Cy5.5,
CF 680, and incubated with nanoparticles for 24 hours. The labeling of the nanoparticles
requires easy "click" chemistry without the introduction of other reagents. Furthermore,
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upon seeing success in vitro, the same dye is often used in vivo for studying nanoparticle
distribution.[142]

Figure 4.8 shows representative images obtained from confocal microscopy. Actin was
stained with phalloidin Alexa Fluor 488 (green) while the nuclei were stained with
propidium iodide (blue). As a comparison, the bright field images and NIRF-channel
(magenta) images are shown for comparison for both the control and the cells incubated
with nanoparticles. Population of the nanoparticles were seen in various planes and were
seen inside the cells, as opposed to sticking to the outside. The bright field images are
qualitative and show that the overall morphology of the cells is maintained, even after
incubation with the nanoparticles. The current resolution of such microscopy will not
distinguish single nanoparticles, but signals from aggregates within a cell population can
be found. This limitation is inherent in studying nanoparticles, and silica-based
nanoparticles are difficult in their detection without a probe.
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Figure 4.8. 20X magnification of cells incubated with PBS (left) and 350 ug/mL of
nanoparticles (right) for 24 hours. (Top) Bright field images, (middle) NIRF channel
showing nanoparticle aggregates, and (bottom) merged image. Actin is seen in green,
nuclei are blue, and nanoparticle aggregates within the cells are shown in magenta.
Nanoparticles are seen in various regions of the cells.
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4.3.5

ROS generation in C8-B4 cells

C8-B4 cells are a microglial cell line with macrophage markers and characteristics. They
were obtained from mice and have been shown to have phagocytic properties.[143]
Determining how the macrophage-like cells react to nanoparticles is important for
clinical translation. Upon activation, such cells release inflammatory factors, ROS, and
RNS.[144]

C8-B4 cells were exposed to mPEG-Hz nanoparticles for 24 hours and stained with DHE
and Hoechst 33342 (Figure 4.9). The cells reacted negatively to the nanoparticles, despite
the PEG coating. The amount of ROS increased significantly as the amount of
nanoparticles increased. A similar experiment with only PEG did not produce such a
response (data not shown). Therefore, it is likely that the cells are reacting to the
nanoparticles.
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C8-B4 ROS response to nanoparticles after 24
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Figure 4.9. ROS production in C8-B4 cells after exposure to mPEG-Hz nanoparticles. All
but the lowest concentration affected the response of the cells. ROS production was
increased, suggesting activation of the microglial cells. (mean ± SE; *P < 0.01)

4.3.6

C8-B4 cell viability after nanoparticle incubation

The microglial cells showed an increase production of ROS with the nanoparticles. It was
critical to look at their viability (Figure 4.10). The viability of the cells decreased
significantly as the nanoparticle concentration increased. The cell number was mostly
consistent, with the exception of the largest concentration. Contrary to the response from
the B35 cells, there is a larger amount of dead cells within the population rather than
demonstrating a high viability and low cell number. The concentrations affecting the C8B4 cells were much lower than those that affected the B35 cells, showing a increased
sensitivity to the nanoparticles by cells involved in an immune response.
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C8-B4 cell response to nanoparticles after 24 hr
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Figure 4.10. Viability and cell number of C8-B4 cells after exposure to nanoparticles.
Similar to the ROS results, all but the lowest concentration affected the viability, but cell
number was only affected in the highest concentration. (mean ± SE; *P < 0.01)

Figure 4.11 contains the LEAP images obtained for the C8-B4 cells. The increase in ROS
production at 100 ug/mL of nanoparticles is clearly evident, as is the significant decrease
in cell number. Morphologically, the C8-B4 cells become more rounded and larger, likely
from "eating" large numbers of nanoparticles. Additionally, if the cells are dying from
exposure to the nanoparticles, they may be "eating" the dead cells. Additional studies,
such as confocal microscopy, may give an indication of what is causing activation: the
nanoparticles or nearby cell death from the nanoparticles.
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Figure 4.11. LEAP images of C8-B4 cells incubated with nanoparticles for 24 hours.
ROS increases with the nanoparticle concentration, and cell number decreases.

4.3.7

ROS generation in co-culture of B35 and C8-B4 cells

ROS was produced in C8-B4 cells upon incubation with the nanoparticles. A co-culture
model was devised with 30% of seeded cells containing the C8-B4 cells, and the
remaining cells were the B35 neurons. Similar concentrations were used at those used
with only C8-B4 cells: 25 ug/mL-100 ug/mL. Similar to the results with C8-B4 cells, all
of the concentrations produced some ROS, with the exception of the lowest concentration
of 25 ug/mL (Figure 4.12). The ROS level was much lower than that seen in just the C8B4 cells, but the production of ROS could lead to problems with the normal cells.
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Co-culture (B35/C8-B4) ROS response to
nanoparticles after 24 hr
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Figure 4.12. ROS response to nanoparticles after 24 hours in co-culture with B35 neurons
and C8-B4 microglial cells. Thirty percent of seeded cells were C8-B4 cells. ROS was
affected in all but the lowest concentration of nanoparticles used. (mean ± SE; *P < 0.01)

4.3.8

Cell viability in co-culture after nanoparticle incubation

Beyond looking at the ROS production, the viability and cell number were also studied in
the co-culture model. The C8-B4 cells had a decrease in both, but in the co-culture
model, no significant effects were observed (Figure 4.13). In the case of the co-culture
model, two factors are likely involved in the reduced response. First, the amount of
microglial cells is significantly lower. Additionally, the neurons are likely taking in the
nanoparticles, reducing the amount for the microglial cells to uptake and react to
negatively. The nanoparticle numbers used in the assays are still lower than most of those
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needed for therapeutic delivery. The LEAP images in Figure 4.14 show the slight
increase in ROS observed.

Co-culture (B35/C8-B4) cell response to
nanoparticles after 24 hr
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Figure 4.13. Viability and cell number in co-culture model after nanoparticle exposure.
None of the concentrations used significantly affected the viability or the cell number.
The number of neuronal cells versus microglial cells likely reduced the negative response
observed with only the microglial cells. (mean ± SE; P > 0.01)
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Figure 4.14. LEAP images of co-culture incubated with nanoparticles for 24 hours. The
ROS levels increase significantly, but viability and cell number were not affected.

4.4

Concluding summary

Toxicity experiments have indicated little toxicity to B35 cells after 24 hours. Based on
the studies, the largest concentrations of the mPEG-hydrazide nanoparticles affect the
overall cell number, but do not decrease overall viability or cause high levels of ROS
production. Furthermore, the nanoparticles were found within the cells after a 24-hour
period. In the case of injured cells with compromised membranes, uptake would present
less of an issue, but if the nanoparticles were to translate for other applications, crossing
into cells would be important.
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In similar experiments with microglial cells, the immune cells of the CNS, a significant
response was observed at concentrations much less than those used for the B35 cells.
High levels of ROS were observed, and both viability and cell number decreased. In a coculture model with both types of cells, ROS was affected, but cell number and viability
were not. Fortunately, the numbers used were lower than those needed for therapeutic
delivery.

With the current knowledge, though, any in vivo studies would have to account for a
potential immune response that could be elicited by the nanoparticles. The model may
also be useful for studying different nanoparticle formulations. Determining a
nanoparticle formulation that reduces the negative response would give an indication of
efficacy early in a study. Additional discussion can also be found in the reference by
White-Schenk et al. (2014).[145]
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CHAPTER 5. AIM III: EXPLORE NATURAL PRODUCTS AS POTENTIAL
ACROLEIN SCAVENGERS

5.1

Introduction

Catechins are complex, natural flavanoid molecules found in various plant products. The
most abundant source of catechins are extracted from green tea leaves, but they are also
found in wines and fruits in lower concentrations. Catechins are related via two adjoining
rings connected to a separate benzyl alcohol, but differ in the hydroxylation on the B ring
and substitution on the C ring (Figure 5.1).
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Figure 5.1 Basic structure of catechin (above) and table of common catechin derivatives.
Chirality not shown.

Various work has looked at the properties of catechins, mainly of EGCG, as it is the most
abundant catechin in green tea extracts. The major focus has been to study their strong
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antioxidant and anti-inflammatory properties. Specifically, the heavily substituted C ring
can be oxidized, forming quinone-like molecules, thus preventing the oxidation of critical
proteins and structures in a cell.[146, 147, 148, 149] Along with their promising
antioxidant ability, they exhibit extremely low toxicity and are classified as GRAS
products.

Although they exhibit these characteristics, the exact mechanisms of action are elusive.
Additionally, their metabolism produces many metabolites and has various methods of
uptake in vivo. Generally, their half life is a short three hours.[146, 150, 151] To try to
increase the availability and activity of the catechins, various groups have modified and
studied the activity of new compounds made from a catechin. Most of the conjugations
occur using an enzyme catalyst, such as horseradish peroxidase or laccase, which allows
the catechin to form a Schiff base with an amine-containing compound or form polymeric
chains. For instance, groups have conjugated catechin to various polymers or structures.
[152, 153, 154, 155] In other studies, researchers have synthesized polymeric
catechins.[156, 157, 158, 159, 160]

For the purpose of the current research, catechins may help alleviate symptoms of
acrolein-induced oxidative stress. Catechins, specifically EGCG, have been shown to
react and reduce acrolein and similar ROS compounds effectively.[149, 161, 162] If one
proves to be a more successful scavenger of acrolein for spinal cord injury, it may open a
new path of research using a natural product.
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5.2
5.2.1

Materials and methods

B35 rat neuroblastoma cell culture

B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture
Collection) and cultured in T-25 or T-75 flasks with DMEM (ATCC) supplemented with
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in
concentrations from 1:4 to 1:8. For all experiments, cells were used in the log phase of
growth.

5.2.2

2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging

To evaluate free radical scavenging capability, effectiveness against 2,2-diphenyl-1picrylhydrazyl (DPPH), a stable free radical, was measured. DPPH forms a dark purple
solution with a peak absorbance at 517 nm. A stock solution of DPPH was prepared in
ethanol. Catechin hydrate, epigallocatechin gallate (EGCG), and hydralazine were all
purchased from Sigma and used as received. Solutions of each compound were prepared
in bubbled PBS. For each reaction, done in three replicates, 50 µL of DPPH in ethanol
was added to 50 µL of catechin, EGCG ,or hydralazine for a final DPPH concentration of
200 µM. The reactions were shaken at room temperature in the dark for 45 minutes
before the absorbance was read at 517 nm and 690 nm using a VersaMax microplate
reader (Molecular Devices, LLC, Sunnyvale, CA). The concentration of each reaction
was calculated using a standard curve of DPPH in 1:1 (v/v) of ethanol/PBS. The
scavenged percentage was calculated as follows:
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5.2.3

Lactate dehydrogenase (LDH) assay for membrane integrity

Epigallocatechin gallate was purchased from Sigma and used as received. A stock
solution of EGCG was prepared and bubbled in sterile ethanol. Directly before use, the
stock was diluted to the appropriate concentrations in PBS. To determine if EGCG is an
effective scavenger of acrolein, the LDH Toxicology Kit was purchased from Sigma and
used per the manufacturer's instructions. B35 cells were seeded in triplicates at 5 x 10 5
cells/mL in DMEM with 10% FBS overnight. A freshly-prepared solution of acrolein in
PBS was added to the cells and incubated for 30 minutes before the addition of EGCG.
The vehicle used for the controls contained the highest EtOH concentration based on the
dilution of EGCG, which was less than 1.5%. After 4 hours with EGCG, the LDH
activity was measured using a VersaMax microplate reader (Molecular Devices, LLC,
Sunnyvale, CA) To determine the total LDH amount, a set of untreated cells were lysed
using 0.5% Triton-X. The data is reported as a change of LDH activity compared to the
lysed control wells, calculated as follows:

5.2.4

Statistical analysis

To determine statistical significance, ANOVA was performed on each data set. For pairwise comparisons, a test using the Least Significant Difference (LSD) was used. P-values
less than 0.01 were considered significant.
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5.3

Results and discussion
5.3.1 DPPH scavenging

In order to evaluate the each compound's ability to quench free radicals, the change in
DPPH concentration was measured in various reactions with each compound. In solution,
DPPH remains a dark purple color until being quenched, where it turns yellow. Because
the reaction with EGCG occurs very rapidly, low molar ratios were chosen to evaluate
the compounds against a larger amount of DPPH.

Figure 5.2 shows the free radical quenching of each compound. The inset shows a typical
standard concentration curve for DPPH. Only at the two highest concentrations of 20 and
40 µM were all three compounds able to remove a significant amount of DPPH after 45
minutes. EGCG removed significantly more DPPH at all concentrations, with the
exception of 40 µM, where hydralazine and EGCG were not significantly different.
Catechin hydrate and hydralazine had similar performances. Compared to the other two
molecules, EGCG has higher nucleophilic capabilities with an increasing number of
hydroxyl groups that can donate electrons and be stabilized with π-bonds from the
aromatic rings to form quinone-like products.
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Figure 5.2. DPPH Scavenging with catechin, EGCG, and hydralazine. Different
concentrations of catechin, EGCG, and hydralazine were reacted with 200 µM of DPPH
for 45 minutes. The absorbance of DPPH at 517 nm was measured. The inset shows a
representative standard curve used to calculate the remaining DPPH concentration.
Displayed is the mean of three reactions + SE. There were no significant differences
between hydralazine and catechin.

5.3.2

Evaluating efficacy using the LDH assay

Especially for acrolein scavenging, maintaining membrane integrity is vital for keeping
cells healthy. To determine if catechin or EGCG could prevent damage by acrolein, cells
were incubated with acrolein for 30 minutes before the addition of treatment, which was
left for four hours (Figures 5.3 and 5.4). For comparison, the data for hydralazine is
shown in conjunction with catechin. Hydralazine prevented damage by acrolein while
catechin showed no benefit against acrolein. A similar experiment with catechin being
applied both before and after exposure to the same hydrogen peroxide concentration did
not improve LDH results (data not shown).
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LDH Assay: Hydralazine and Catechin against Acrolein in
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Figure 5.3. Acrolein scavenging with catechin and hydralazine via LDH. Acrolein was
added to the cells before the addition of treatment. Catechin showed no benefit against
acrolein, unlike hydralazine.

In a similar experiment, all of the samples containing EGCG were similar to the vehicle
control whereas the untreated cells exposed to acrolein had significant damage. The
results indicate that EGCG was able to prevent damage to the cells (Figure 5.4). Such
results are likely due to the high scavenging ability of EGCG compared to other
catechins, which has been shown previously.[149, 162] Therefore, in later studies, EGCG
was used against acrolein rather than catechin.
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Acrolein scavenging with EGCG in B35 cells
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Figure 5.4. Acrolein scavenging with EGCG via LDH. 50 uM of acrolein was added to
B35 cells for 30 minutes before the application of EGCG for 4 hours. All concentrations
were able to prevent acrolein from causing intense damage and cell death.

5.4

Concluding summary

Two natural products, catechin and epigallocatechin gallate, were explored for their
ability to prevent cell damage via acrolein. Although catechin outperformed hydralazine
in a free radical assay, against acrolein, it did not provide any benefit whereas both
hydralazine and EGCG significantly reduced damage caused by acrolein. In future
studies, both hydralazine and EGCG will be used to determine if their efficacy and
availability can be improved using the silica nanoparticles described in previous chapters.
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CHAPTER 6. AIM IV: EXPLORE THERAPY-NANOPARTICLE INTERACTIONS
IN A CELL-FREE SYSTEM

6.1

Introduction

Before adding nanoparticles to a complicated cell system, demonstrating the ability of the
nanoparticles to act as a vehicle system for therapeutic delivery is essential. The
experiments in this aim were used to determine whether the therapeutic would interact
with the nanoparticles. Once an interaction could be established, it is necessary to
determine how the interaction affects the nanoparticles, particularly their size
distribution.

6.2
6.2.1

Materials and methods

Reflective hyperspectral imaging for hydralazine loading of mPEG-amine
nanoparticles

For hydralazine loading, 3 mg of the synthesized mPEG-Am in PBS was shaken with 75
mM solution of hydralazine hydrochloride (Sigma, St. Louis) in PBS. Samples for
reflective hyperspectral imaging (RHI) were sent to Cytoviva, Inc in Arab, AL. Samples
of 75 mM hydralazine, mPEG-amine nanoparticles, and hydralazine-loaded nanoparticles
were analyzed and the spectra were obtained and compared. Hydralazine and mPEGamine nanoparticles were mapped in the sample of the loaded nanoparticles.
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6.2.2

Size of loaded nanoparticles

Solutions of 1 mg/mL of nanoparticles were loaded with hydralazine (1600 ug/mL, 25%
EtOH) at concentrations of 0 ug/mL, 100 ug/mL, 250 ug/mL, and 500 ug/mL,
corresponding to 0, 10, 25 and 50-percent loading by mass. The hydrodynamic diameter
of the nanoparticle population was measured using a Malvern Zetasizer ZS. An average
of three measurements was used to determine the average hydrodynamic diameter.

6.3
6.3.1

Results and discussion

Reflective hyperspectral imaging for hydralazine loading of mPEG-amine
nanoparticles

Hydralazine has been shown to scavenge for acrolein; therefore, loading the nanoparticles
provides a therapy that will stop the secondary injury cascade, which affects both the
injured and surrounding healthy tissue, caused by acrolein. Reflective hyperspectral
imaging was used to confirm loading of hydralazine. A sample of the nanoparticles
loaded with hydralazine was analyzed for the presence of the drug. When the sample was
mapped, no unassociated nanoparticle could be found in solution, indicating a successful
interaction with the nanoparticles (Cytoviva, email communication). The spectra are
shown in Figure 6.1. The mixture of hydralazine with the nanoparticles shows
characteristics of both the pure drug and the nanoparticles. Because there is free
hydralazine in the solution, the spectrum is closer to that of pure hydralazine than the
nanoparticles.
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Figure 6.1. Spectra of hydralazine-loaded nanoparticles via reflective hyperspectral
imaging. X-axis shows wavelength from 400-1000 nm. The right spectrum is the mPEGAm nanoparticles; the left spectrum is that of hydralazine, and the middle spectrum is the
mixture of the two. Image and analysis provided by Cytoviva, Inc. (Arab, AL).

6.3.2

Size of loaded nanoparticles

Nanoparticles were diluted to a concentration of 1 mg/mL and loaded with a stock
solution of hydralazine. The average hydrodynamic diameter and PDI is shown in Table
6.1. As the concentration of hydralazine increased, the size of the nanoparticles increased.
Based on how the average diameter is calculated, the 25% loaded sample shows an
average of 34.4 nm, but the sample contained two populations of similar intensity: 18 nm
and 56 nm. It is possible the concentration was similar to that in a buffered titration
curve, and at 50% loading, it has overcome the threshold to have a more uniform
distribution of nanoparticles with hydralazine. The PDI increases between the 10% and
25%-loaded nanoparticles but decreases again in the 50%-loaded sample.
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Table 6.1. Size of mPEG-Hz nanoparticles loaded with hydralazine.
Loading (%)
0
10
25
50

Diameter (nm)
14.18
15.68
34.40
275.9

6.4

St. Dev. (nm)
2.23
0.95
2.41
13.91

PDI
0.262
0.285
0.302
0.295

Concluding summary

The work presented in this aim demonstrates that the therapeutic interacts with the
nanoparticles. Furthermore, the size of the nanoparticles interacting with various
concentrations of hydralazine was investigated for future studies in vitro. In further
studies, studies were performed only using mPEG-Hz nanoparticles loaded with 50%
treatment by mass.
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CHAPTER 7. AIM V: EVALUATE THE EFFICACY OF NANOPARTICLES IN
VITRO.

7.1

Introduction

Ultimately, the goal of the nanomedical system is the delivery of therapeutics for
oxidative stress attenuation. In order to properly evaluate the performance of the
nanoparticles, a proper in vitro system must be utilized. An important aspect of spinal
cord injury is distinguishing between the original, primary injury, which is inevitable, and
the secondary biological injury. In looking at the nanoparticle efficacy, it is important to
evaluate the performance of the nanoparticle-therapy system against the therapy alone.
This final aim describes the process of creating an appropriate in vitro model system for a
primary-to-secondary injury followed by the evaluation of the original hypothesis: silica
nanoparticles will improve the delivery of therapeutics.

7.2
7.2.1

Materials and methods

B35 rat neuroblastoma cell culture

B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture
Collection) and cultured in T-25 or T-75 flasks with DMEM (ATCC) supplemented with
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in
concentrations from 1:5 to 1:10. For all experiments, cells were used in the log phase of
growth.
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7.2.2

C8-B4 mouse glioblastoma cell culture

C8-B4 mouse glioblastoma cells were obtained from ATCC (American Tissue Culture
Collection) and cultured in T-25 with DMEM (ATCC) supplemented with 10% FBS
(Invitrogen). The cells were co-cultured twice per week and were seeded in
concentrations from 1:3 to 1:4. For all experiments, cells were used in the log phase of
growth.

7.2.3

Lactate dehydrogenase (LDH) assay for membrane integrity

To confirm hydralazine as an effective scavenger of acrolein, the LDH Toxicology Kit
was purchased from Sigma and used per the manufacturer's instructions. B35 cells were
seeded in triplicates at 5 x 105 cells/mL in DMEM with 10% FBS overnight. A freshlyprepared solution of acrolein in PBS was added to the cells and incubated for 30 minutes
before the addition of hydralazine. After 4 hours, the LDH activity was measured using a
VersaMax microplate reader (Molecular Devices, LLC, Sunnyvale, CA) To determine
the total LDH amount, a set of untreated cells were lysed using 0.5% Triton-X. The data
is reported as a change of LDH activity compared to the lysed control wells, calculated as
follows:

7.2.4

Primary stress model using Fe(II)

B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 105 cells/mL
in DMEM with 10% FBS. FeSO4 in DMEM was added to a final concentration of 100
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uM incubated for 30 minutes before the addition of hydralazine, EGCG, or vehicle. After
24 hours post iron exposure, the cells were washed with PBS twice, and they were
incubated in 10 uM DHE and 2 uM calcein am in PBS for 30 minutes. The dyes were
washed away, and the cells were analyzed in DMEM with 10% FBS and 5 ug/mL
Hoechst 33342. The analysis settings were optimized on LEAP using the positive and
negative controls before obtaining data from all samples. The data was exported for postprocessing in Excel.

7.2.5

Evaluating efficacy against LPO using DHE and cell viability

B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 105 cells/mL
in DMEM with 10% FBS. FeSO4 in DMEM was added to a final concentration of 20 uM
incubated for 30 minutes before the addition of hydralazine, nanoparticles, hydralazineloaded nanoparticles, or EGCG-loaded nanoparticles. Four hours after the addition of
iron, 15 uM acrolein was added in PBS. After 24 hours post iron exposure, the cells were
washed with PBS twice, and they were incubated in 10 uM DHE and 2 uM calcein am in
PBS for 30 minutes. The dyes were washed away, and the cells were analyzed in DMEM
with 10% FBS and 10 ug/mL Hoechst 33342. The analysis settings were optimized on
LEAP using the positive and negative controls before obtaining data from all samples.
The data was exported for post-processing in Excel.

7.2.6 Evaluating cellular responses to loaded nanoparticles
B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 105 cells/mL
(20,000 cells/well) in DMEM with 10% FBS. Hydralazine, EGCG, hydralazine-loaded
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nanoparticles, and EGCG-loaded nanoparticles were delivered using PBS and incubated
for 24 hours. After 24 hours, the cells were washed with PBS twice, and they were
incubated in 10 uM DHE and 2 uM calcein am in PBS for 30 minutes. The dyes were
washed away, and the cells were analyzed in DMEM with 10% FBS and 10 ug/mL
Hoechst 33342. The analysis settings were optimized on LEAP using the positive and
negative controls before obtaining data from all samples. The data was exported for postprocessing in Excel.

7.2.7

Statistical analysis

To determine statistical significance, ANOVA was performed on each data set. For pairwise comparisons within ANOVA sets, a test using the Least Significant Difference
(LSD) was used. P-values less than 0.01 were considered significant.

7.3
7.3.1

Results and discussion

Confirming hydralazine as an acrolein scavenger

Before beginning to evaluate the nanoparticles a proper model had to be established that
would simulate how acrolein behaves in vivo. In the most basic model, acrolein was
added directly to the cells, treatment was added after 30 minutes, and the membrane
integrity was analyzed using the lactate dehydrogenase assay. Over a very short period,
this confirmed that hydralazine was hindering damage from acrolein (Figure 7.1).
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Acrolein scavenging with Hydralazine in B35 cells
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Figure 7.1. Acrolein attenuation with hydralazine. Membrane damage caused by acrolein
was significantly decreased after incubation with hydralazine for 4 hours. (*P < 0.01)

When the model was moved to more complex assays, though, it was found to be
problematic. The ROS levels remained high (data not shown), indicating the cells were in
the process of either recovering or dying. The LDH merely indicated fewer damaged or
necrotic cells overall, but gave no indication of how the cells were dealing with the stress
of the acrolein exposure. The model also lacked the "primary injury" aspect that would be
found in a spinal cord injury or an MS attack. In the direct acrolein model, the compound
was assumed to play the role of both the primary and secondary injury.

7.3.2

Cell stress after exposure to Fe(II)

To begin to address the shortcomings of the previous model, cells were exposed to
ferrous iron, which has been used to induce and simulate lipid peroxidation in vitro.[163,
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164, 165] If successful, the iron could be used to induce a "primary injury" followed by
smaller doses of acrolein. Therefore, the cell behavior was evaluated after using only iron
and trying to treat with hydralazine and EGCG (Figures 7.2 and 7.3).
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Figure 7.2. Hydralazine performance after ferrous iron exposure. Cells were exposed to
iron(II) and then evaluated for ROS and viability. All samples were significantly different
from the control for all parameters: viability, ROS, and total cell number.

In the 24-hour assay, the cells had significantly higher levels of ROS, lower levels of
viability, and fewer cells after exposure to the iron. The results are promising in that cells
were dying, but the ROS level was not drastically high, which should change with
exposure to acrolein. Hydralazine was only slightly affective against the iron exposure.
The higher concentrations were detrimental, and only the lowest concentration was
significantly helpful at preserving the cell number, viability, and reducing the ROS.
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Figure 7.3. EGCG performance after ferrous iron exposure. Cells were exposed to
iron(II) and then evaluated for ROS and viability. All samples were significantly different
from the control for all parameters: viability, ROS, and total cell number.

Alternately, the EGCG had a mostly neutral performance against the iron exposure.
Similar to the higher hydralazine concentrations, the EGCG was detrimental to the cell
population, and the highest (75 uM) actually increased the ROS level in the cell
population. The overall viability increased, but the it merely indicates that dead cells had
likely undergone apoptosis rather than remaining dead in the well (necrotic) in the
positive control. Overall, the iron caused a significant amount of cellular loss and death
that could lead to a better model to simulate first primary injury followed by secondary
injury.
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7.3.3 Iron and acrolein in vitro model
The next in vitro model first utilized the iron to induce a "primary" injury followed by a
dose of acrolein for "secondary" injury. The acrolein was added on a 4-hour delay after
the iron exposure based on previous work indicating that acrolein levels rise over a 24hour period in vivo.[166] In the experiments involving nanoparticles, nanoparticles were
loaded 50% by mass with the therapy of interest. The final concentration of therapy
added to the cells was converted to mass by volume to determine the appropriate mass of
therapy and nanoparticles to be incubated together. For instance, in the 2.5 uM
hydralazine sample, the hydralazine mass/volume is 0.2 ug/mL. Therefore, 0.2 ug/mL of
hydralazine was loaded in 0.4 ug nanoparticles/mL for the concentration corresponding to
2.5 uM. The control samples were exposed to the highest concentration of empty
nanoparticles.
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Figure 7.4. Delayed acrolein model using hydralazine and hydralazine-loaded
nanoparticles. The change in cell number indicates an interaction between hydralazine
and the nanoparticles. (Symbols indicate P < 0.01.)

In the experiment with hydralazine and hydralazine-loaded nanoparticles, the viability
and ROS changed little in the treatment samples, but the cell number varied with the
hydralazine level (Figure 7.4). In the samples with nanoparticles, the cell number does
not improve with the application of treatment. The two lowest hydralazine concentrations
showed a significant increase in cell number before declining again. Based on the
controls, the empty nanoparticles did not change the cell number in either the negative
(vehicle) or positive controls. On a separate note, the model shows that the iron and
acrolein concentrations used affected the cell population slightly, but using both of them
was more significant than the iron alone.
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Therefore, it is hypothesized that some interaction between the nanoparticles and
hydralazine changed the behavior of the hydralazine to affect the cell population. More of
the cells are dying, which could be from very slow drug release. In the case of this model,
a bolus dose of acrolein is added to the cells. Since the nanoparticles are not delivering a
bolus dose of therapy, it could reasonably be explained that the cells will continue to die
from the iron and acrolein exposure until they receive a reasonable amount of therapy to
prevent cell death. Either higher nanoparticle concentrations or a slower dose of acrolein
may be necessary to properly assess the nanoparticle behavior.
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Figure 7.5. Delayed acrolein model using EGCG and EGCG-loaded nanoparticles. The
cell number in all nanoparticle samples was significantly different from the positive
control (Fe/Acrolein). (Symbols indicate P < 0.01.)
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The results with EGCG were more complex than those of hydralazine-loaded
nanoparticles. (Figure 7.5) Similarly, though, the empty nanoparticles did not affect the
cell population. In the nanoparticle-treated samples, the viability and cell number
decreased compared to the positive control. The cell number leveled, but the viability
continued to decrease. Additionally, the ROS in the two highest concentrations with
nanoparticles was significantly increased compared the positive control. (Figure 7.6)
Overall, the experiment did not show any benefit in using EGCG, but the nanoparticles
changed the cell behavior even more significantly. One explanation for the poor EGCG
results could stem from its apoptotic and pro-oxidant activity seen in cancer cells, which
would obviously confound the study.[147] If that is the case, the nanoparticles may be
"protecting" the EGCG from oxidation and prolonging its activity.
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Figure 7.6. ROS of delayed acrolein model using EGCG and EGCG-loaded
nanoparticles. EGCG-loaded nanoparticles in the highest concentrations adversely
affected the recovery of the cells, creating more oxidative stress. (Symbols indicate P <
0.01.)

7.3.4 Cellular responses to loaded nanoparticles
Because the nanoparticles showed no advantage over the treatments alone, various
problems may account for the lack of efficacy:

1) The interaction of the nanoparticles and the therapeutic negatively affects the
cell behavior through a change in either a physical or chemical characteristic.
2) The nanoparticles may be releasing the treatment too slowly to overcome the
bolus dose of acrolein in the models, resulting in an increase in cell death before the
concentration becomes effective. In the case of EGCG, it prolongs the activity of EGCG,
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which can become a pro-oxidant and pro-apoptotic compound at high enough
concentrations, negatively affecting the cells even further.
3) The cell model is not ideal for the type of in vivo problem that is being
simulated.
4) The nanoparticles may need to be improved through a different synthesis
method, their size, or some other characteristic.

In an attempt to test first of these hypotheses, the cells were incubated with the treatments
and treatment-loaded nanoparticles and toxicity assays were performed after 24 hours.
The results for hydralazine are shown in the Figure 7.7. The cells incubated with
hydralazine-loaded nanoparticles behaved no differently than those exposed only to
hydralazine. The ROS data was similar (Figure 7.8).
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Figure 7.7. Viability and cell number from the interaction of hydralazine and the
nanoparticles. None of the concentrations showed differences that were statistically
significant.
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Figure 7.8. ROS results from the interaction of hydralazine and the nanoparticles. None
of the concentrations showed differences that were statistically significant.

The interaction was not detrimental to the cells, but it does not address the hypothesis that
the nanoparticles may be releasing the treatments slowly, both extending their activity
and keeping the concentration too low to be beneficial against acrolein. On the other
hand, the experiment with EGCG proved slightly different (Figures 7.9 and 7.10). At
high concentrations, EGCG can become a pro-oxidant rather than an antioxidant.
Additionally, in solution, EGCG will polymerize or undergo modifications. For most of
the concentrations, the EGCG was not problematic. With EGCG alone, 50 uM was
detrimental to cells in both ROS production and cell number. The next lowest
concentration, 37.5 uM was detrimental only to the cell number. On the other hand, at
both 37.5 uM and 50 uM with the nanoparticles, the ROS was increased, which suggests
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a higher pro-oxidant activity when loaded into the nanoparticles, and the cell number was
decreased, which was similar to the free EGCG.
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Figure 7.9. Viability and cell number after 24 exposure to EGCG-loaded nanoparticles.
The cell number was decreased in all samples with 37.5 uM and 50 uM EGCG, including
those with nanoparticles.

The nanoparticles may be protecting the EGCG from degradation. Additionally, it is
more difficult to predict the response of a therapeutic when the cells are likely taking up
the nanoparticles. With cells "eating" the nanoparticles, the effective concentration may
be higher in some of the cells than in others. It would increase the EGCG concentration
in certain cells that uptake the nanoparticles, making the EGCG more effective in those
cells.
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Figure 7.10. ROS production of EGCG-loaded nanoparticles. ROS was increased in the
50 uM, EGCG-only sample, but the ROS was increased in both the 37.5 uM and 50 uM
samples with EGCG-loaded nanoparticles.

7.4

Concluding summary

The current aim attempted to demonstrate the feasibility of using the silica nanoparticles
for therapeutic delivery against acrolein or ROS induction in B35 neuroblastoma cells.
The current experiments demonstrated a change in therapeutic activity when loaded into
the nanoparticles, but the change was to the detriment of the cells. Properly identifying
the "unknown factor" in the nanoparticle-therapeutic interaction would provide insight
into how the nanoparticles need to be changed to improve delivery. The efficacy was
especially hindered in studies with the natural product EGCG. Those studies

96
demonstrated a worsening of the ROS and cell death upon loading the EGCG in to the
nanoparticles.

Various hypothesis were tested to potentially determine how the "unknown factor"
affects the therapeutically-loaded nanoparticles. Toxicity studies with the loaded
nanoparticles were not found to affect the cells, but a change in activity was found with
nanoparticles loaded with EGCG. Using already detrimental concentrations of EGCG, the
delivery of EGCG using the nanoparticles worsened the effects of the EGCG. The
increased damage corroborates that the nanoparticles affect the delivery of the
therapeutic, seemingly increasing the activity, but the precise factors in the interaction are
unknown and will require further study.

Furthermore, the detriment may stem from the limitation of the cell models at hand. The
complexity of in vivo problems is obvious, and attempting to study such problems using
in vitro models is extremely primitive at best. A functioning co-culture model of
inflammation, such as with the neuronal cells and microglial cells, would have provided
an additional layer of complexity, but admittedly, the conditions in vivo are still
unrivalled in an in vitro co-culture system.
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CHAPTER 8. CONCLUSION

8.1

Concluding remarks

The project described herein had five specific aims to attempt to address how a
nanomedical system may be used to mitigate the effects of neuronal injury caused by
oxidative species.

Aim I: Design, synthesize, and characterize hybrid silica nanoparticles.
The silica nanoparticles were successfully synthesized over the course of the project. Not
only was the synthesis repeatable with high efficiency, but the nanoparticles remained
shelf-stable for long periods of time. The synthesis allowed the PEG to be incorporated
onto the outside of the silica network during the initial formation, eliminating the need
for a second step to add the stealth polymer. The synthesis also allowed for easy
fluorescence labeling of the PEG product. Two different PEG products, including from
different manufacturers, had similar results in size distribution and stability under the
same synthetic conditions, further supporting the utility of such a synthetic scheme. For
additional avenues of study, researchers can change the PEG product, most notably the
molecular weight, to explore the ideal formulation for their applications.
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Aim II: Evaluate the toxicity of nanoparticles in vitro.
The silica nanoparticles were found to exhibit low toxicity in the B35 neuroblastoma line,
but they caused a significant ROS response in C8-B4 glioblastoma cells. When cultured
together, the ROS response was attenuated by the reduced number of microglial cells.
Overall, single-cell studies were better indicators for studying the cellular response, as
many of the studies found artificially high viability counts, but deeper analysis into cell
number found a change in cellular behavior. The nanoparticle concentrations found to
cause detrimental effects in both the monoculture and co-culture systems were higher
than those used for therapeutic delivery, but future improvements in the nanoparticles
should aim to address toxic responses, such as those seen in the co-culture system, and
reduce it.

Aim III: Explore natural products catechin and epigallocatechin gallate as potential
acrolein scavengers.
Preliminary studies demonstrated that EGCG may be a better candidate for acrolein
scavenging than hydralazine, but catechin performed similarly to hydralazine. In vitro
studies with hydrogen peroxide and acrolein demonstrated that hydralazine outperformed
catechin in preventing cell damage. On the other hand, EGCG prevented acrolein damage
in lower concentrations than those needed for similar prevention with hydralazine. The
increased scavenging is attributed to the molar ratios needed for scavenging acrolein.
Hydralazine can only react with one acrolein molecule, whereas EGCG can react with
two or three molecules of acrolein. Therefore, studies with EGCG were continued in later
aims of the project.
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Aim IV: Explore therapy-nanoparticle interactions in a cell-free system.
Before moving to an in vitro system, the ability of the nanoparticles to undergo loading
and interact with hydralazine was studied. Dynamic light scattering studies found that the
nanoparticles had a concentration-dependent size change when loaded with hydralazine.
Additionally, using reflective hyperspectral imaging, hydralazine could be found
interacting with the nanoparticles. Following these experiments, the nanoparticles were
further studied for their delivery properties in vitro in the project's final aim.

Aim V: Evaluate the efficacy of nanoparticles in vitro.
The nanoparticles were found to change the delivery of the therapeutics in a cell model
using iron as a primary injury agent followed by a "secondary injury" of acrolein. The
change in the delivery was not ideal to save the cells from extensive injury and was found
to be less effective than the therapeutics alone. The lack of efficacy may be attributed to
an improper in vitro model. The nanoparticles decidedly require improvements
(discussed in the next section) and will require numerous studies to understand the
interaction and delivery of the nanoparticles within tissue culture and how such
interactions translate to in vivo conditions.

8.2

Future work and recommendations

These approaches address some of the SCI problems and show promise of using a
nanomedical approach, but they can be improved. Using nanoparticles to address some of
the secondary injury problems shows the promise of using a nanomedical approach, but
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both the delivery systems and therapeutics require improvement. In terms of secondary
SCI, many of the problems have been identified, but the optimal treatment has yet to be
determined and methylprednisolone, even with its problems and side effects, is the only
treatment in clinical use specifically for SCI and MS. Therefore, attempting to mitigate
its side effects using nanomedicine has a distinct advantage in pushing both the treatment
of SCI and nanomedicine forward. On the other hand, the need for better treatments is
self-evident, but those treatments are waylaid by a lack of clinical results. The research
route of administering an unapproved treatment using nanomedicine is decidedly difficult
but likely promising in clinical translation. Additionally, scientists have much work in
convincing government agencies, the pharmaceutical industry, and the public regarding
the toxicity of nanotechnology in a general sense. Beyond that, they must then be
convinced that nanomedical systems are beneficial to expand the current research efforts
and drive improvements in the technology through research.

The project at hand will require fine-tuning of the nanoparticles to improve the
therapeutic delivery response, which is a major limitation seen in studies up to this point.
Because of the synthesis technique of silica nanoparticles, commercial companies have
begun to make them available for researchers. Unfortunately, though, most modifications,
such as PEGylation, then must be done by the scientist. Changing commercial
nanoparticles would allow for a systematic study of different PEG polymers for the
optimum characteristics of delivery and cytotoxicity. In the current study, the synthesis
relies on the presence of PEG to reduce synthesis steps, but a more sophisticated process
may be necessary to achieve sustained release and reduced toxicity. New commercial
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siloxane products are available containing PEG, but researchers are again limited by the
compounds sold by chemical suppliers unless they want undertake their own synthetic
methods. One group has established a synthetic protocol where the nanoparticle work-up
and purification occurs via dialysis at room temperature for about a week using a
commercial, PEGylated siloxane. They utilize the surfactant used in the traditional
synthesis, but the surfactant removal occurs in acid at room temperature followed by
buffer exchange whereas the traditional route involved refluxing in acidic solvent, solvent
removal, and suspension in the appropriate buffer.[167] By keeping the nanoparticles in
solution, it reduces the aggregation seen in many solvent-removal schemes.

With improved delivery, more positive results may be obtained from EGCG or other
natural products. Their limited use is well known already, and an improvement in
delivery using nanomedicine would likely push the efficacy of natural products much
further. Other directions with EGCG include conjugating the compound to the
nanoparticle, which could also increase its absorption. Various synthetic work has been
done to add moieties to EGCG. Based on its molecular structure, many click chemistry
reactions would likely be useful, as well.

Another limitation of the study involved the lack of a valid cellular model for spinal cord
injury. Further work should explore and determine a model that exhibits similar
characteristics in vitro. Most models of spinal cord injury rely on animal studies, and the
literature shows a wide array of in vitro models only scarcely related to what happens in
vivo. Part of the secondary biochemical cascade includes inflammation; therefore, a co-
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culture model using both neurons and supporting cells would be a closer, albeit primitive,
model to the problems observed in vivo. By studying the inflammatory response and
biological responses in the in vitro model, one may be able to improve the nanoparticles
and therapeutics even further. For instance, aldehyde-reactive probes and antibodies for
acrolein-modified proteins could highlight the type of damage being induced in the coculture model. Upon classifying the damage, the nanoparticles could be specifically
tailored to mitigate the immune response or to fight the oxidative stress. The nanomedical
system would be much more specific to the biological response.
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 Biochemistry and molecular biology:
 PCR, cloning, mutagenesis, enzyme kinetics, and electrophoresis (SDS, agarose),
bacterial culture
 Analysis:
 Atomic absorption, infrared spectroscopy, UV/Visible spectroscopy, NMR
General Motors
Warren/Pontiac, MI
January 2008- March 2009
Materials Testing co-op student
 Performed tests based on GM, ASTM, and SAE specifications
 Trained on numerous test methods used in automotive industry
 Completed and submitted reports based on test results
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Chemical Analysis:
 Inductively-coupled plasma, x-ray fluorescence, thermogravimetric analysis

Durant Tuuri Mott School
Flint, MI
October 2007- June 2011
h ’
 Instructed middle school students in various subjects
 Helped teacher complete tasks with grading and lessons

Theses
White-Schenk D. Silica Nanoparticles as Vehicles for Therapy Delivery in Neurological
Injury. Ph.D. thesis. Weldon School of Biomedical Engineering, Purdue University,
2014.
White D. Porous Polymers and their Uses for Hydrogen Storage. B.S. thesis. Department
of Chemistry and Biochemistry, Kettering University and Chemical Sciences and
Engineering, Argonne National Laboratory, 2011.

Publications
White-Schenk D, Shi R, Leary JF (Undergoing revisions) Nanomedicine Strategies for
Treatment of Neuronal Injury and Degeneration. International Journal of Nanomedicine.
Wang L, Santos E, Schenk D, Rabago Smith M (2014) Kinetics and Mechanistic Studies
on the Reaction between Cytochrome C and Tea Catechins. Antioxidants. In press. doi:
10.3390/antiox3030559
Yuan S, White D, Mason A, Liu DJ (2013) Porous organic polymers containing
carborane for hydrogen storage. International Journal of Energy Research. doi:
10.1002/er.1886
Yuan S, White D, Mason A, Reprogle B, Ferrandon M, Yu L, Liu DJ (2011) Improving
Hydrogen Adsorption Enthalpy through Coordinatively Unsaturated Cobalt in Porous
Polymers. Macromol. Rapid Comm. doi: 10.1002/marc.201100797
Smith MR, Atkinson P, White D, Piersma T, Gutierrez G, Rossini G, Desai S,
Wellinghoff S, Yu H, Cheng X (2011) Design and assessment of a wrapped cylindrical
Ca-P AZ31 Mg alloy for critical-size ulna defect repair. J. Biomed. Mater. Res. B Appl.
Biomater. doi: 10.1002/jbm.b.31940
White, D and Rabago Smith, M (2011) Genotype-phenotype Associations and Human
Eye Color: A review. J. Hum. Genetics. doi: 10.1038/jhg.2010.126
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Yuan S, Dorney B, White D, Kirklin S, Zapol P, and Liu DJ. (2010) Microporous
polyphenylenes with tunable pore size for hydrogen storage. Chem. Comm. 46(25):45479

Conference Proceedings
White-Schenk D, Shi R, Leary JF (Accepted and in preparation) Interactions of silica
nanoparticles with therapeutics for oxidative stress attenuation in neurons. Invited paper
at SPIE Photonics West. February 2015.
White-Schenk D, Leary JF, Shi R (2014) Mediating the potent ROS toxicity of acrolein
in neurons with silica nanoparticles and a natural product approach. Invited paper
presented at SPIE Photonics West. Feb. 1-4, 2014. Proc. of SPIE Vol. 8956 89560C-1
White-Schenk D, Leary JF, Shi R (2013) Mesoporous silica nanoparticles for treating
spinal cord injury. Invited paper presented at SPIE Photonics West. Feb. 2-5, 2013. Proc.
of SPIE Vol. 8587 858716-1.

Selected Presentations
White-Schenk D, Shi R, Leary JF (2014) Mediating the potent ROS toxicity of acrolein
in neurons with silica nanoparticles and a natural product approach. Invited talk presented
by JFL at SPIE BiOS. February 1-4, 2014.
White-Schenk D, Shi R, Leary JF (2013) The Design of Silica Nanoparticles for
Oxidative Stress Attenuation in Neurons. Poster presentation at American Chemical
Society national conference. September 8-12, 2013.
White-Schenk D, Shi R, Leary JF (2013) Designing and nalyzing nanoparticles for drug
delivery. Poster presentation for Next Generation Research Scholars program at Purdue
University. April 2013.
White-Schenk D, Shi R, Leary JF (2013) Mesoporous silica nanoparticles for treating
spinal cord injury. Invited paper presented at SPIE BiOS. February 2-5, 2013.
White D, Shi R, Leary JF (2012) Design and characterization of mesoporous silica
nanoparticles for treating spinal cord injury. Purdue's OIGP Spring Reception. April 4,
2012. Certificate of Excellence program award.
Rabago Smith M, White D, Piersma T, LeCronier D, Ostrander J, Mosier-Laclair S,
Cheng X. (2010) Decomposition Study of Magnesium Alloys. Poster presentation at
Michigan Orthopedic Society Conference.
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White D, Piersma T, LeCronier D, Houghtaling J, Mosier-Laclair S, Cheng X, and
Rabago Smith M. (2010) Study of Toxicity and degradation of coated magnesium alloys
in rats. Research presentation at Flint Area Medical Education Conference.
Piersma T, White D, LeCronier D, Cheng X, and Rabago Smith M. (2010) In Vitro
Decomposition Study of Magnesium Coated Alloys. Research presentation at Flint Area
Medical Education Conference, American Physics Society meeting at Kettering
University, and American Chemical Society regional meeting and Oakland University.
White D, Piersma T, LeCronier D, Cheng X, and Rabago Smith M. (2010) In Vivo
Decomposition of Magnesium Alloys. Poster Presentation at American Physics Society
meeting at Kettering University.
White D, Piersma T, and Rabago Smith M. (2010) Optimization of Magnesium alloy
coatings and decomposition. Poster presentation at American Chemical Society regional
meeting at Oakland University.

Honors and Awards
NSF Graduate Research Fellow
Lynn Doctoral Fellow, Purdue University
President’s Medal Recipient, Kettering University
Outstanding Thesis Award, Kettering University
Dean’s List
Kettering Presidential Scholarship

(2014)
(2011)
(2011)
(2007-2011)
(2007-2011)

Professional Organizations
American Chemical Society (ACS)
Society of Photo-Optical Engineers (SPIE)
Biomedical Engineering Graduate Student Association
Gamma Sigma Epsilon Chemistry Honor Society

Leadership
Discovery Park Graduate Ambassador
BME Graduate Student Association Outreach Committee Chair
Women in Engineering BME Ambassador
Interdisciplinary Graduate Programs Advisory Board Member

(2013-2014)
(2012-2014)
(2012-2014)
(2013-2014)

